MX353234B - Polypeptide variants with altered effector function. - Google Patents

US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants MX353234B (en) 1999-01-15 2018-01-08 Genentech Inc Polypeptide variants with altered effector function. US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof DK1355919T3 (en) 2000-12-12 2011-03-14 Medimmune Llc Molecules with longer half-lives, compositions and uses thereof US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins US7511121B2 (en) * 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin DE60232265D1 (en) * 2001-10-25 2009-06-18 Genentech Inc GLYCOPROTEIN COMPOSITIONS US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants JP4524181B2 (en) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド CD16A binding protein and use for treatment of immune disorders US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof DK1553975T3 (en) * 2002-09-27 2012-05-07 Xencor Inc Optimized Fc variants and methods for their generation. US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis DK1562972T3 (en) 2002-10-15 2010-12-06 Facet Biotech Corp Modification of FcRn binding affinities or serum half-lives for antibodies by mutagenesis US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME AU2011265460B2 (en) * 2003-01-09 2014-07-17 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants ES2322267T3 (en) 2003-04-09 2009-06-18 Genentech, Inc. THERAPY OF AN AUTOINMUNOLOGICAL DISEASE IN A PATIENT THAT PRESENTS AN INAPPROPRIATE RESPONSE TO A TNF-ALFA INHIBITOR. JP4685764B2 (en) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis KR100973564B1 (en) * 2003-05-02 2010-08-03 젠코어 인코포레이티드 Optimized Fc Variants and Methods of Making the Same US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof RU2396981C2 (en) 2003-07-24 2010-08-20 Иннейт Фарма Methods and compositions for improving effectiveness of antibody for medical application with using compounds potentiating nk-cells US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions JP2007531707A (en) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions RS55723B1 (en) 2003-11-05 2017-07-31 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto WO2005051289A2 (en) * 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof KR101374514B1 (en) 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ip-10 antibodies and their uses EP2418220B1 (en) 2003-12-10 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses DK1706424T3 (en) 2004-01-12 2009-11-02 Applied Molecular Evolution FC region variants AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region EP2067789A1 (en) * 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies AU2005244058B2 (en) 2004-05-10 2011-07-28 Macrogenics, Inc. Humanized FcgammaRIIB specific antibodies and methods of use thereof KR100545720B1 (en) * 2004-05-31 2006-01-24 메덱스젠 주식회사 Glycated immunoglobulins and immunoconjugates comprising them MXPA06014069A (en) 2004-06-04 2007-04-25 Genentech Inc Method for treating multiple sclerosis. CN101001878B (en) 2004-06-21 2012-09-26 米德列斯公司 Interferon alpha receptor 1 antibodies and their uses MX2007000404A (en) * 2004-07-12 2008-03-04 Macrogenics Inc Identification and engineering of antibodies with variant fc regions and methods of using the same. US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS AU2005272993B2 (en) * 2004-07-15 2010-02-11 Xencor, Inc. Optimized Fc variants WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions JP2008510007A (en) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド Eph receptor Fc variants with enhanced antibody-dependent cellular cytotoxic activity US20060067930A1 (en) * 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function KR20070100228A (en) 2004-10-05 2007-10-10 제넨테크, 인크. How to treat vasculitis JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations. AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn KR101019525B1 (en) 2004-11-12 2011-03-07 젠코어 인코포레이티드 Fc VARIANTS WITH ALTERED BINDING TO FcRn US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life MX2007008017A (en) * 2004-12-31 2007-09-12 Genentech Inc Polypeptides that bind br3 and uses thereof. JP2008528486A (en) 2005-01-21 2008-07-31 ジェネンテック・インコーポレーテッド Fixed dose of HER antibody US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders EP1853718B1 (en) 2005-02-15 2015-08-05 Duke University Anti-cd19 antibodies and uses in oncology RU2404806C2 (en) 2005-02-23 2010-11-27 Дженентек, Инк. Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors EP3153525A1 (en) 2005-03-23 2017-04-12 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof ES2971647T3 (en) 2005-04-15 2024-06-06 Macrogenics Inc Covalent diabodies and their uses US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics KR20080046135A (en) 2005-05-20 2008-05-26 제넨테크, 인크. Pretreatment of Biological Samples from Autoimmune Disease Subjects JP2008546805A (en) 2005-06-23 2008-12-25 メディミューン，エルエルシー Antibody formulations with optimal aggregation and fragmentation profiles CN101252951B (en) 2005-06-30 2011-12-21 森托科尔公司 Anti-IL-23 antibodies, compositions, methods and uses KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1) CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam JP2009501913A (en) * 2005-07-21 2009-01-22 ゲンマブ エー／エス Efficacy assays for antibody drug substances that bind to Fc receptors EP1919505A2 (en) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules CA2616395C (en) 2005-07-25 2016-10-04 Trubion Pharmaceuticals B-cell reduction using cd37-specific and cd20-specific binding molecules EP2573114B1 (en) * 2005-08-10 2016-03-30 MacroGenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same BR122020020335B1 (en) 2005-08-26 2023-10-03 Roche Glycart Ag ANTI-CD20 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies PL2532679T3 (en) 2005-10-21 2017-09-29 Novartis Ag Human antibodies against il13 and therapeutic uses MX360959B (en) 2005-11-04 2018-11-23 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases. AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays ES2388932T3 (en) 2005-12-02 2012-10-19 Genentech, Inc. Binding polypeptides and uses thereof NZ712762A (en) 2005-12-02 2017-03-31 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r KR101446510B1 (en) 2005-12-08 2014-10-20 메다렉스, 엘.엘.시. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 US7981414B2 (en) 2005-12-20 2011-07-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb ES2517420T3 (en) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, procedures and uses KR101589391B1 (en) 2006-01-05 2016-01-29 제넨테크, 인크. Anti-ephb4 antibodies and methods using same SI1976884T1 (en) 2006-01-20 2013-04-30 Genetech, Inc. Anti-ephrinb2 antibodies and methods using same CN103232540A (en) 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 Domain antibody construct WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies US20100080794A1 (en) * 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function JP2009538629A (en) 2006-05-30 2009-11-12 ジェネンテック・インコーポレーテッド Antibodies and immunoconjugates and methods for their use CL2007001623A1 (en) 2006-06-06 2008-01-18 Genentech Inc Anti-dll4 antibody; polynucleotide that encodes it; vector and host cell comprising said polynucleotide; method for making the antibody and immunojugate; method of detection of dll4 and diagnostic method of a disorder associated with dll4; composition comprising the antibody. EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function LT2029173T (en) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses ME01786B (en) 2006-08-14 2014-09-20 Xencor Inc Optimized antibodies that target cd19 WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use PL2066349T3 (en) 2006-09-08 2012-09-28 Medimmune Llc Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases WO2008033782A2 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Antibody having enhanced adcc activity and method for production thereof CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24 ES2625798T3 (en) 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Human antibodies that bind to CXCR4 and their uses PE20080980A1 (en) * 2006-10-12 2008-09-02 Genentech Inc ANTI-LYMPHOTOXIN ALPHA ANTIBODIES AU2007313300A1 (en) * 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof CA2666682C (en) 2006-10-19 2014-07-08 Merck & Co., Inc. Anti-il-13r.alpha.1 antibodies and their uses thereof PL2829551T3 (en) 2006-10-19 2018-04-30 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1 RU2639543C9 (en) 2006-10-27 2018-06-14 Дженентек, Инк. Antibodies and immunoconjugates and their applications US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides RU2474589C9 (en) 2006-11-02 2019-08-15 Дженентек, Инк. Humanised anti-factor d antibodies and use thereof CA2669921A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof US20080127996A1 (en) * 2006-12-04 2008-06-05 Weinhold Dennis G Method and apparatus to remediate an acid and/or liquid spill US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof EP2101807B1 (en) 2006-12-19 2016-05-25 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors AU2008208288B2 (en) 2007-01-24 2014-04-03 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 MX2009008430A (en) 2007-02-09 2009-10-28 Genentech Inc Anti-robo4 antibodies and uses therefor. JP2010520225A (en) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド Method for predicting response to HER dimerization inhibitors based on low HER3 expression ES2910298T3 (en) 2007-03-08 2022-05-12 Humanigen Inc Antibodies against EphA3 for the treatment of solid tumors ES2713859T3 (en) 2007-03-22 2019-05-24 Biogen Ma Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, which bind specifically to CD154 and uses thereof WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody TW200902547A (en) 2007-04-27 2009-01-16 Genentech Inc Potent, stable and non-immunosuppressive anti-CD4 antibodies WO2008137475A2 (en) * 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease US20100233167A1 (en) * 2007-05-10 2010-09-16 Ramesh Bhatt Chain reaction creating oligomers from repeat units of binding molecules CN101720232B (en) 2007-05-14 2013-07-10 诺维莫尼公司 Fc receptor-binding polypeptides with modified effector functions AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells EP2666787B1 (en) * 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment CL2008001741A1 (en) * 2007-06-12 2008-11-21 Genentech Inc Chimeric or humanized antibody or fragment thereof that specifically bind to at least one epitope in the beta-amyloid protein; nucleic acid molecule that encodes it; composition that includes it; and its use to treat diseases associated with the formation of amyloid plaques. US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody MX2009013816A (en) 2007-06-21 2010-02-24 Macrogenics Inc Covalent diabodies and uses thereof. CA2692392A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- mcp-1 antibodies, compositions, methods and uses WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides EP2078091A4 (en) * 2007-07-10 2010-09-01 Medimmune Llc CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use US8088378B2 (en) 2007-07-16 2012-01-03 Genetech Inc. Anti-CD79B antibodies and immunoconjugates and methods of use WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof PL2190469T3 (en) 2007-09-04 2015-07-31 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease WO2009054435A1 (en) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. Polypeptide having enhanced effector function EP3305324A1 (en) 2007-11-02 2018-04-11 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) HUE038588T2 (en) 2007-11-07 2018-10-29 Genentech Inc For use in the treatment of IL-22 microbial disorders TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies BRPI0821658B8 (en) 2007-12-14 2021-05-25 Novo Nordisk As human monoclonal antibody or an antigen-binding fragment thereof that binds to hnkg2d and its uses WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173 EP4269443A3 (en) 2007-12-26 2023-12-27 Xencor, Inc. Fc variants with altered binding to fcrn US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof MX2010008437A (en) 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use. NZ587440A (en) 2008-02-05 2013-01-25 Pfizer Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours KR101666229B1 (en) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Anti-ifnar1 antibodies with reduced fc ligand affinity CN112481367A (en) * 2008-03-31 2021-03-12 健泰科生物技术公司 Compositions and methods for treating and diagnosing asthma ES2654937T3 (en) 2008-04-02 2018-02-15 Macrogenics, Inc. Specific antibodies for the BCR complex and procedures for their use US8802093B2 (en) 2008-04-02 2014-08-12 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same HRP20240722T1 (en) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly KR20110013391A (en) 2008-04-11 2011-02-09 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 CD37 immunotherapy and bifunctional chemotherapeutic agents and combinations thereof CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES MX2010011955A (en) * 2008-04-29 2011-01-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof. RU2010153578A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof ES2675730T3 (en) 2008-06-04 2018-07-12 Macrogenics, Inc. Antibodies with altered FcRn binding and methods of use thereof MX2010014574A (en) 2008-07-08 2011-04-27 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof. US20100021460A1 (en) * 2008-07-15 2010-01-28 Genentech, Inc. Methods of Treating Autoimmune Diseases Using CD4 Antibodies DK2328616T3 (en) 2008-08-05 2015-07-20 Novartis Ag Compositions and Methods for Antibodies to Complement Protein C5 AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Method for treating progressive multiple sclerosis RU2581962C2 (en) 2008-09-19 2016-04-20 Медиммун Ллк Targeted binding agents against dll4 and application thereof WO2010045193A1 (en) * 2008-10-14 2010-04-22 Genentech, Inc. Immunoglobulin variants and uses thereof US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1 BRPI0921845A2 (en) 2008-11-12 2019-09-17 Medimmune Llc stable sterile aqueous formulation, pharmaceutical unit dosage form, pre-filled syringe, and methods for treating a disease or disorder, treating or preventing rejection, depleting unique expressing t cells in a human patient, and disrupting central germinal architecture in a secondary lymphoid organ of a primate DK2752189T3 (en) 2008-11-22 2017-01-16 Hoffmann La Roche APPLICATION OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154 EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding ES2733067T3 (en) 2008-12-19 2019-11-27 Macrogenics Inc Covalent diabodies and uses thereof WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists JP2012513194A (en) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use CN102421800A (en) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 Humanized antibodies that bind CD19 and uses thereof BRPI1009232B1 (en) 2009-03-05 2022-05-03 E.R. Squibb & Sons, Llc. Isolated monoclonal antibody or an antigen-binding portion thereof, or an antibody fragment, composition comprising them, nucleic acid molecule, hybridoma and methods for preparing an anti-cadm1 antibody EA201101241A1 (en) 2009-03-06 2012-04-30 Калобайос Фармасьютиклз, Инк. TREATMENT OF LEUKEMIA AND CHRONIC MYELOPROLIFERATIVE DISEASES BY ERP3 Antibodies WO2010105290A1 (en) 2009-03-16 2010-09-23 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants CN102356092B (en) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies CA2756197A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof KR101822663B1 (en) 2009-03-25 2018-01-29 제넨테크, 인크. Anti-fgfr3 antibodies and methods using same ES2363358B1 (en) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AN INDESEABLE CELLULAR PROLIFERATION. SI2417156T1 (en) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalent, bispecific antibodies EA030182B1 (en) 2009-04-20 2018-07-31 Оксфорд Байотерепьютикс Лтд. Antibodies specific to cadherin-17 US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth EA201101572A1 (en) 2009-04-27 2012-05-30 Новартис Аг COMPOSITIONS AND METHODS OF APPLICATION OF THERAPEUTIC ANTIBODIES SPECIFIC TO THE SUB-UNIT OF BETA1 IL-12 RECEPTOR KR20140014382A (en) * 2009-05-01 2014-02-06 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION CN102549016B (en) * 2009-06-30 2015-05-06 研究发展基金会 Immunoglobulin FC polypeptides US20110076271A1 (en) 2009-07-13 2011-03-31 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments BR112012002083A2 (en) 2009-07-31 2016-11-08 Genentech Inc tumor metastasis inhibition SG177689A1 (en) 2009-07-31 2012-02-28 Organon Nv Fully human antibodies to btla AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media WO2011020049A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists AR077848A1 (en) 2009-08-15 2011-09-28 Genentech Inc ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER PREVIOUSLY TREATED WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same JP5887270B2 (en) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド Mutant SMOOTHENED AND METHOD OF USING THE SAME US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells WO2011032013A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent JP5606537B2 (en) 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Methods and compositions for diagnostic use in cancer patients US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule LT2486141T (en) 2009-10-07 2018-05-25 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10 JP2013508292A (en) 2009-10-14 2013-03-07 カロバイオス ファーマシューティカルズ インコーポレイティッド Antibodies against EphA3 AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof JP5814925B2 (en) 2009-10-22 2015-11-17 ジェネンテック， インコーポレイテッド Anti-hepsin antibody and method of use thereof IN2012DN02604A (en) 2009-10-23 2015-09-04 Millennium Pharm Inc WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME SI2496691T1 (en) 2009-11-02 2017-07-31 University of Washington UW Center for Commercialization Therapeutic nuclease compositions and methods JP6077856B2 (en) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Engineered anti-TSLP antibody This application is filed in US provisional application 61 / 297,008 (filed January 21, 2010) and US provisional application 61 / 258,051 (filed November 4, 2009). ), Each of which is incorporated herein by reference in its entirety. RU2585488C2 (en) 2009-11-05 2016-05-27 Дженентек, Инк. Methods and composition for secretion of heterologous polypeptides EP2496257A4 (en) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins SI3279215T1 (en) 2009-11-24 2020-07-31 Medimmune Limited Targeted binding agents against b7-h1 WO2011066501A1 (en) * 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use. IN2012DN05169A (en) 2009-12-02 2015-10-23 Acceleron Pharma Inc EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same KR20120107122A (en) 2009-12-22 2012-09-28 노파르티스 아게 Tetravalent cd47-antibody constant region fusion protein for use in therapy RU2559542C2 (en) 2009-12-23 2015-08-10 Дженентек, Инк. Anti-bv8 antibodies and using them US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof BR112012019902A2 (en) 2010-02-10 2019-09-24 Novartis Ag "method and compounds for muscle growth" RU2587619C2 (en) 2010-02-18 2016-06-20 Дженентек, Инк. Neuregulin antagonists and use thereof in treating malignant growth RU2015102845A (en) * 2010-02-23 2015-06-10 Санофи ANTIBODIES TO α2 INTEGRIN AND THEIR APPLICATIONS AR080244A1 (en) 2010-02-23 2012-03-21 Genentech Inc ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIC CANCER US9260529B2 (en) 2010-02-24 2016-02-16 The University Of Washington Through Its Center For Commercialization Molecules that bind CD180, compositions and methods of use JP5820800B2 (en) 2010-03-02 2015-11-24 協和発酵キリン株式会社 Modified antibody composition PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof ME03447B (en) 2010-03-04 2020-01-20 Macrogenics Inc ANTIBODIES REACTING WITH B7-H3, ASSOCIATED IMMUNOLOGICALLY ACTIVE FRAGMENTS AND ASSOCIATED USES AR080795A1 (en) 2010-03-24 2012-05-09 Genentech Inc ANTI-LRP6 ANTIBODIES (PROTEIN RELATED TO THE LDL RECEIVER TYPE 6) US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders NZ602634A (en) 2010-03-26 2015-06-26 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use CN102971340A (en) * 2010-03-29 2013-03-13 酵活有限公司 Antibodies with enhanced or suppressed effector function EP4501956A2 (en) 2010-03-30 2025-02-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules that promote antigen clearance TWI667346B (en) * 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof CN103080130B (en) 2010-05-27 2016-08-17 默沙东公司 Preparation has the method for the antibody improving characteristic WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor WO2011159980A1 (en) 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use HUE044419T2 (en) 2010-07-09 2019-10-28 Bioverativ Therapeutics Inc Processable single chain molecules and polypeptides made using same SG187119A1 (en) 2010-07-19 2013-02-28 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy JP2013538338A (en) 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Methods for identifying patients with increased likelihood of response to anti-cancer therapy WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use RU2598711C2 (en) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Anti-tumour antigen antibody and methods of application EP3696195B1 (en) 2010-07-23 2024-02-14 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery HRP20230776T1 (en) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Chimeric il-1 receptor type i antagonists NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody MX2013001302A (en) 2010-08-03 2013-03-08 Hoffmann La Roche Chronic lymphocytic leukemia (cll) biomarkers. BR112013002578A2 (en) 2010-08-03 2019-05-14 Abbvie Inc. double variable domain immunoglobins and their uses CN103209709A (en) 2010-08-05 2013-07-17 弗·哈夫曼-拉罗切有限公司 Anti-MHC antibody anti-viral cytokine fusion protein WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use LT2603530T (en) 2010-08-13 2018-01-25 Roche Glycart Ag Anti-fap antibodies and methods of use JP5841149B2 (en) 2010-08-13 2016-01-13 ロシュ グリクアート アーゲー Anti-tenascin CA2 antibody and method of use WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use ES2620255T3 (en) 2010-08-20 2017-06-28 Novartis Ag Antibodies for epidermal growth factor 3 receptor (HER3) WO2012025536A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof KR20130139884A (en) 2010-08-26 2013-12-23 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use UY33578A (en) 2010-08-31 2012-03-30 Sanofi Sa PEPTIDE PEPTIDE OR COMPLEX THAT JOINS INTEGRINE TO (ALPHA) AND METHODS AND USES THAT INVOLVE THE SAME WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment NZ608814A (en) 2010-09-03 2015-06-26 Stem Centrx Inc Novel modulators and methods of use KR20140019284A (en) 2010-09-03 2014-02-14 아카데미아 시니카 Anti-c-met antibodies and methods of use thereof WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics WO2012041800A1 (en) 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl EP2625197B1 (en) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened and methods of using the same CN103154037A (en) 2010-10-05 2013-06-12 诺瓦提斯公司 Anti-IL 12 Rbeta 1 antibodies and their use in treating autoimmune and inflammatory disorders MX354095B (en) 2010-10-13 2018-02-12 Janssen Biotech Inc Human oncostatin m antibodies and methods of use. CN103534268B (en) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 Antibody KR101973930B1 (en) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain TWI603738B (en) 2010-11-08 2017-11-01 建南德克公司 Subcutaneously administered anti-il-6 receptor antibody MX346500B (en) 2010-11-10 2017-03-22 Genentech Inc * Methods and compositions for neural disease immunotherapy. PT2643352T (en) 2010-11-23 2018-08-01 Glaxo Group Ltd Antigen binding proteins to oncostatin m (osm) US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia EP2643351A1 (en) 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf KR20240025059A (en) * 2010-11-30 2024-02-26 추가이 세이야쿠 가부시키가이샤 Cytotoxicity-inducing therapeutic agent RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules TWI689314B (en) 2010-11-30 2020-04-01 建南德克公司 Low-affinity blood-brain barrier receptor antibody and its use SG190990A1 (en) 2010-12-08 2013-07-31 Stem Centrx Inc Novel modulators and methods of use BR112013015122A2 (en) 2010-12-15 2017-05-30 Wyeth Llc anti-notch1 antibodies MY188365A (en) 2010-12-16 2021-12-06 Genentech Inc Diagnosis and treatments relating to th2 inhibition CA2819269A1 (en) 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates TW201307391A (en) 2010-12-22 2013-02-16 Genentech Inc anti-PCSK9 antibody and method of use thereof DK2654780T3 (en) * 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS CN102128937B (en) * 2010-12-31 2014-05-28 江苏华冠生物技术股份有限公司 Evaluating and monitoring method for effect of desensitization therapy, detection kit of allergen specificity IgG4 antibody and preparation method thereof WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc Aldehyde-tagged immunoglobulin polypeptides and method of use thereof US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use SG192945A1 (en) * 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody WO2012132067A1 (en) 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity AR085403A1 (en) 2011-02-28 2013-09-25 Hoffmann La Roche MONOVALENT PROTEINS THAT JOIN ANTIGENS RU2013140975A (en) 2011-02-28 2015-04-10 Дженентек, Инк. BIOLOGICAL MARKERS AND METHODS FOR PREDICTING SUSCEPTIBILITY TO B-CELL ANTAGONISTS CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins US8969526B2 (en) * 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants CN113999307A (en) 2011-03-30 2022-02-01 中外制药株式会社 Methods for altering plasma retention and immunogenicity of antigen binding molecules AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule KR20130137688A (en) 2011-03-31 2013-12-17 제넨테크, 인크. Methods of administering beta7 integrin antagonists BR112013024717A2 (en) 2011-04-07 2017-08-08 Genentech Inc isolated antibody, isolated nucleic acid, host cell, immunoconjugate, pharmaceutical formulation, method of treating an individual who has cancer and method of inhibiting cell proliferation in an individual HUE033008T2 (en) 2011-04-13 2017-11-28 Bristol Myers Squibb Co FC fusion proteins containing new linkers JP2014517685A (en) 2011-04-15 2014-07-24 コンピュゲン エルティーディー． Polypeptides and polynucleotides and their use for the treatment of immune related diseases and cancer LT2699264T (en) 2011-04-20 2018-07-10 Medimmune, Llc Antibodies and other molecules that bind b7-h1 and pd-1 CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica GB201107170D0 (en) 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition EP2704737B1 (en) 2011-04-29 2018-01-10 University of Washington Therapeutic nuclease compositions and methods WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides ES2657862T3 (en) 2011-05-13 2018-03-07 Gamamabs Pharma Antibodies against HER3 EP2710035B1 (en) 2011-05-16 2017-04-12 F. Hoffmann-La Roche AG Fgfr1 agonists and methods of use MX347818B (en) 2011-05-21 2017-05-15 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life. CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3 CN103857699B (en) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 Multivalence and unit price polyspecific complex and application thereof EP2714732A4 (en) 2011-05-25 2014-12-10 Merck Sharp & Dohme PROCESS FOR THE PREPARATION OF Fc-CONTAINING POLYPEPTIDES WITH ENHANCED PROPERTIES WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8 RU2013158627A (en) 2011-06-15 2015-07-20 Ф. Хоффманн-Ля Рош Аг ANTIBODIES TO THE HUMAN ERYTHROPOETIN RECEPTOR AND WAYS OF THEIR APPLICATION EP2721073A1 (en) 2011-06-16 2014-04-23 Novartis AG Soluble proteins for use as therapeutics KR20140104944A (en) 2011-06-22 2014-08-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Anti-axl antibodies and uses thereof AU2012273955A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof CA2835772C (en) 2011-06-22 2020-12-01 F. Hoffmann-La Roche Ag Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2 BR112013030472A2 (en) 2011-06-30 2019-09-24 Genentech Inc pharmaceutical formulation, article of manufacture and method RU2641256C2 (en) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Heterodimerizated polypeptide CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection ES2692519T3 (en) 2011-07-01 2018-12-04 Novartis Ag Method to treat metabolic disorders UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS JP2014526886A (en) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー Antibodies cross-reactive with macrophage migration inhibitory factor (MIF) and D-dopachrome tomerase (D-DT) US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS BR112014001855A2 (en) 2011-07-27 2017-02-21 Glaxo Group Ltd antigen-binding construct and protein, dimer, pharmaceutical composition, polynucleotide sequence, host cell and method for construct production JP6120848B2 (en) 2011-08-15 2017-04-26 メディミューン，エルエルシー Anti-B7-H4 antibody and use thereof WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof EP2744825A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Inhibition of angiogenesis in refractory tumors BR112014003999A2 (en) 2011-08-23 2017-06-13 Roche Glycart Ag isolated antibody that binds to a near epitope near the human mcsp membrane, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating cancer patients, unduction method of cell lysis in individuals and mcsp immunohistochemical test US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation KR20140064971A (en) 2011-09-19 2014-05-28 제넨테크, 인크. Combination treatments comprising c-met antagonists and b-raf antagonists EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities JP6352634B2 (en) 2011-09-30 2018-07-04 中外製薬株式会社 Antigen-binding molecules that induce immune responses to target antigens US20140335089A1 (en) 2011-09-30 2014-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens PT2760471T (en) 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Therapeutic peptides TW201817745A (en) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance WO2013052155A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists EP3617313A1 (en) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain CN108373506A (en) 2011-10-14 2018-08-07 霍夫曼-拉罗奇有限公司 Anti- HtrA1 antibody and application method ES2769786T3 (en) 2011-10-14 2020-06-29 Recordati Ag Antibodies and methods for diseases related to the Wnt pathway KR20140084164A (en) 2011-10-15 2014-07-04 제넨테크, 인크. Scd1 antagonists for treating cancer WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE RECOMBINANT PRODUCTS AND USES THEREOF AU2012328980A1 (en) 2011-10-28 2014-04-24 Genentech, Inc. Therapeutic combinations and methods of treating melanoma KR102398736B1 (en) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies RS62689B1 (en) 2011-11-04 2021-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain WO2013070565A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof AR088920A1 (en) 2011-11-21 2014-07-16 Genentech Inc ANTI-C-MET ANTIBODY PURIFICATION KR20140125351A (en) 2011-11-23 2014-10-28 이제니카 바이오테라퓨틱스, 인크. Anti-cd98 antibodies and methods of use thereof CN113416257A (en) 2011-11-30 2021-09-21 中外制药株式会社 Drug comprising transporter (carrier) that enters into cell to form immune complex CN108341873B (en) 2011-12-05 2022-03-25 诺华股份有限公司 Antibodies to epidermal growth factor receptor 3(HER3) AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides JP2015500829A (en) 2011-12-05 2015-01-08 ノバルティス アーゲー HER3 antibody against domain II of epidermal growth factor receptor 3 (HER3) US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation WO2013101509A2 (en) 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof ES2816078T3 (en) 2011-12-20 2021-03-31 Medimmune Llc Modified Polypeptides for Bispecific Antibody Scaffolds EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5 AR089434A1 (en) 2011-12-23 2014-08-20 Genentech Inc PROCEDURE TO PREPARE FORMULATIONS WITH HIGH CONCENTRATION OF PROTEINS US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17 CN104520321A (en) 2012-01-09 2015-04-15 斯克利普斯研究所 Ultralong complementarity determining regions and uses thereof CN104411717A (en) 2012-01-09 2015-03-11 斯克利普斯研究所 Humanized antibodies with ultralong CDR3S CN104271150A (en) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof BR112014017320A2 (en) 2012-01-13 2018-05-29 Genentech Inc method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder US20130183294A1 (en) 2012-01-18 2013-07-18 Genentech, Inc. Methods of using fgf19 modulators TW201335187A (en) 2012-01-18 2013-09-01 Genentech Inc Anti-LRP5 antibodies and methods of use IN2014KN00848A (en) 2012-02-01 2015-10-02 Compugen Ltd RU2656183C2 (en) 2012-02-07 2018-05-31 Иннейт Фарма Mica binding agents KR102148303B1 (en) 2012-02-11 2020-08-26 제넨테크, 인크. R-spondin translocations and methods using the same EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same EP2818183B1 (en) 2012-02-24 2020-04-01 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc RIIB EP3093294A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors LT2831113T (en) 2012-03-28 2018-06-25 Sanofi Antibodies to bradykinin b1 receptor ligands EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd Anti-lamp5 antibody and utilization thereof AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS MX2014011582A (en) 2012-03-30 2014-11-21 Genentech Inc Diagnostic methods and compositions for treatment of cancer. BR112014024769A2 (en) 2012-04-05 2017-12-12 Ac Immune Sa humanized antibody tau US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay CN104662042A (en) 2012-05-07 2015-05-27 赛诺菲 Method for preventing biofilm formation WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide TR201810930T4 (en) 2012-05-18 2018-08-27 Genentech Inc High concentration monoclonal antibody formulations. MY181743A (en) 2012-05-21 2021-01-06 Genentech Inc Methods for improving safety of blood-brain barrier transport JP6294311B2 (en) 2012-05-23 2018-03-14 ジェネンテック， インコーポレイテッド How to select a treatment WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules WO2013174927A1 (en) 2012-05-23 2013-11-28 Novartis International Pharmaceutical Limited Production of fucosylated glycoproteins WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy CN104487457B (en) 2012-05-30 2018-01-26 中外制药株式会社 Target tissue specific antigen binding molecule EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens JP6321633B2 (en) 2012-06-04 2018-05-09 ノバルティス アーゲー Site-specific labeling method and molecules produced thereby JP2015525222A (en) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Chimeric coagulation factor EP2859019B1 (en) 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Humanized anti-trka antibodies with amino acid substitutions EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION CA2875096A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use KR20150023826A (en) * 2012-06-21 2015-03-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function WO2013192504A1 (en) 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES RU2630296C2 (en) 2012-07-04 2017-09-06 Ф. Хоффманн-Ля Рош Аг Antibodies to biotin and application methods ES2600154T3 (en) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use NZ701040A (en) 2012-07-04 2017-02-24 Hoffmann La Roche Covalently linked antigen-antibody conjugates EP3578660A1 (en) 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Expression and secretion system US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof CN104736174B (en) 2012-07-06 2019-06-14 根马布私人有限公司 Protein dimer with triple mutant EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations CA2874904A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies AU2013288932A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies EA201590174A1 (en) 2012-07-09 2015-09-30 Дженентек, Инк. IMMUNOCONGATES CONTAINING ANTI-CD22 ANTIBODIES US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates PT2882450T (en) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof HRP20211641T1 (en) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases JP2015528802A (en) 2012-07-18 2015-10-01 グリコトープ ゲーエムベーハー Novel therapeutic treatment using anti-HER2 antibody with low fucosylation DK3381943T3 (en) 2012-07-25 2022-05-16 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND USES THEREOF EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody JP6501521B2 (en) 2012-08-24 2019-04-17 中外製薬株式会社 FcγRIIb-specific Fc region variant CN109053901A (en) 2012-08-29 2018-12-21 霍夫曼-拉罗奇有限公司 blood-brain barrier shuttle body JOP20200308A1 (en) 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules CN109793893B (en) 2012-09-07 2023-05-26 达特茅斯大学理事会 VISTA modulators for diagnosis and treatment of cancer US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function CN104797601B (en) 2012-09-12 2019-08-30 建新公司 The polypeptide comprising FC of glycosylation and reduced effector function with change JP2015533832A (en) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド Anti-C16orf54 antibody and method of use thereof CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3 CA2890483A1 (en) 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof CN104968367B (en) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 Antihemagglutinin antibody and application method EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities EP2925779A1 (en) 2012-11-30 2015-10-07 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock WO2014089111A1 (en) 2012-12-05 2014-06-12 Novartis Ag Compositions and methods for antibodies targeting epo ES2780398T3 (en) 2012-12-10 2020-08-25 Biogen Ma Inc Anti-blood dendritic cell antigen 2 antibody and use thereof SG11201504764SA (en) 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses RU2650756C2 (en) 2012-12-21 2018-04-17 МЕДИММЬЮН, ЭлЭлСи Antibodies to h7cr SG11201504414UA (en) 2012-12-21 2015-07-30 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients JP6433297B2 (en) 2012-12-27 2018-12-05 中外製薬株式会社 Heterodimerized polypeptide US9938344B2 (en) 2012-12-28 2018-04-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer CN105102067B (en) 2013-01-02 2020-03-03 艾科诺斯科技股份有限公司 Antibodies that bind TL1A and uses thereof WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9 KR20240123420A (en) 2013-01-10 2024-08-13 젠맵 비. 브이 Human igg1 fc region variants and uses thereof WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof AU2014209994B2 (en) 2013-01-24 2017-03-16 Glaxosmithkline Intellectual Property Development Limited TNF-alpha antigen-binding proteins TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies comprising chimeric constant domains EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma KR102447350B1 (en) 2013-02-08 2022-09-23 노파르티스 아게 Specific sites used to modify the antibody for the production of immunoconjugates BR112015017338B1 (en) 2013-02-08 2022-11-29 Novartis Ag ISOLATED THERAPEUTIC HUMAN ANTIBODY OR ANTIGEN-BINDING PORTION THEREOF, ITS USE AND PRODUCTION PROCESS, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEIC ACID MOLECULE, CLONING OR EXPRESSION VECTOR AND TRANSGENIC MICRO-ORGANISM WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates US10183967B2 (en) 2013-02-12 2019-01-22 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods ES2751735T3 (en) 2013-02-12 2020-04-01 Bristol Myers Squibb Co Protein refolding methods at high pH EP3255062B1 (en) 2013-02-14 2019-07-03 Innate Pharma Anti-nkp46 antibody for diganosis of a non-cutaneous peripheral t-cell lymphoma (ptcl) HUE053136T2 (en) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimized factor viii gene CN105026427B (en) 2013-02-20 2019-12-24 依奈特制药公司 Compounds that specifically bind to KIR3DL2 for the treatment of peripheral T-cell lymphoma PL2958944T3 (en) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Antidll3-antibody-pbd conjugates and uses thereof EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance AR094873A1 (en) 2013-02-25 2015-09-02 Genentech Inc METHODS AND COMPOSITIONS TO DETECT AND TREAT MUTANTS OF AKT RESISTANT TO DRUGS RU2015140921A (en) 2013-02-26 2017-04-03 Роше Гликарт Аг ANTIBODIES TO MCSP US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance SG11201506088RA (en) 2013-03-11 2015-09-29 Genzyme Corp Hyperglycosylated binding polypeptides US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates MX2015012404A (en) 2013-03-13 2016-02-03 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery. MX2015010777A (en) 2013-03-14 2016-04-25 Genentech Inc Anti-b7-h4 antibodies and immunoconjugates. EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3 EP2968540A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use RS62304B1 (en) 2013-03-14 2021-09-30 Macrogenics Inc BISPECIFIC MOLECULES WHICH ARE IMMUNOREACTIVE WITH IMMUNE EFFECTIVE CELLS EXPRESSING AN ACTIVATING RECEPTOR US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance BR112015023262B8 (en) 2013-03-15 2024-02-06 Ac Immune Sa Isolated antibody, immunoconjugate, pharmaceutical formulation and uses of antibody US20160017041A1 (en) 2013-03-15 2016-01-21 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies MA38396B1 (en) 2013-03-15 2019-05-31 Novartis Ag Conjugated drug antibodies and their pharmaceutical compositions for treating a ckit positive cancer EA035645B1 (en) 2013-03-15 2020-07-21 Дженентек, Инк. IL-22 POLYPEPTIDES, IL-22 Fc FUSION PROTEINS AND USE THEREOF CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17 WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof SG11201507333XA (en) 2013-03-15 2015-10-29 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions EP4039281A1 (en) 2013-03-15 2022-08-10 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof EP2968541A4 (en) 2013-03-15 2017-02-08 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses MX2015012059A (en) 2013-03-15 2016-01-12 Merck Patent Gmbh Tetravalent bispecific antibodies. KR20150128707A (en) 2013-03-15 2015-11-18 제넨테크, 인크. Compositions and methods for diagnosis and treatment of hepatic cancers JP6397479B2 (en) 2013-03-15 2018-09-26 エータイアー ファーマ， インコーポレイテッド Histidyl-tRNA synthetase Fc conjugate FR3003171B1 (en) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement NOVEL MEDICAMENTS COMPRISING AN ENHANCED ANTIBODY COMPOSITION IN MAJORITY LOAD ENFORCEMENT MX2015011899A (en) 2013-03-15 2016-05-05 Genentech Inc Methods of treating cancer and preventing cancer drug resistance. LT2970464T (en) 2013-03-15 2020-08-25 Glaxosmithkline Intellectual Property Development Limited ANTI-LAG-3 BINDING PROTEINS WO2014144865A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Anti-crth2 antibodies and methods of use CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides AU2014241552B2 (en) 2013-03-27 2018-08-16 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists CN105246914B (en) 2013-04-02 2021-08-27 中外制药株式会社 Fc region variants KR20150144804A (en) 2013-04-22 2015-12-28 글리코토페 게엠베하 Anti-cancer treatments with anti-egfr antibodies having a low fucosylation US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B PT3677591T (en) 2013-04-29 2023-02-17 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b EP3878866A1 (en) 2013-04-29 2021-09-15 F. Hoffmann-La Roche AG Fc-receptor binding modified asymmetric antibodies and methods of use JP2016528167A (en) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Human FcRn binding modified antibody and method of use IL242088B2 (en) 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use CA2927309A1 (en) 2013-05-24 2014-11-27 Promis Neurosciences Inc. Fasr antibodies for diagnostic and therapeutic use CN106414489A (en) 2013-05-24 2017-02-15 米迪缪尼有限公司 Anti-b7-h5 antibodies and their uses US11098105B2 (en) 2013-05-31 2021-08-24 Zymeworks Inc. Heteromultimers with reduced or silenced effector function AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use JPWO2014208482A1 (en) 2013-06-24 2017-02-23 中外製薬株式会社 A therapeutic agent for non-small cell lung cancer other than adenocarcinoma comprising humanized anti-Epiregulin antibody as an active ingredient CN105814074B (en) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof CR20160132A (en) 2013-08-12 2016-08-25 Genentech Inc COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT BR112016002753A2 (en) 2013-08-13 2017-11-21 Sanofi Sa antibodies to plasminogen activator inhibitor-1 (parent-1) and uses thereof TWI592426B (en) 2013-08-13 2017-07-21 賽諾菲公司 Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof ES2871418T3 (en) 2013-08-28 2021-10-28 Abbvie Stemcentrx Llc Compositions and methods of conjugation of site-specific antibodies EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics KR20160055252A (en) 2013-09-17 2016-05-17 제넨테크, 인크. Methods of using anti-lgr5 antibodies EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof JP2016537965A (en) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド NSP4 inhibitors and methods of use EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use AU2014340129A1 (en) 2013-10-23 2016-05-26 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders ES2759252T3 (en) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Nuclease-albumin fusions and therapeutic methods AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use JP6449876B2 (en) 2013-11-07 2019-01-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Anti-human HER3 antibody that is non-competitive and allosteric for neuregulin and uses thereof CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound CN113278076A (en) 2013-11-11 2021-08-20 中外制药株式会社 Antigen binding molecules comprising altered antibody variable regions WO2015073580A1 (en) 2013-11-13 2015-05-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof WO2015075011A1 (en) 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE US10961530B2 (en) 2013-12-04 2021-03-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules KR20160090904A (en) 2013-12-06 2016-08-01 다나-파버 캔서 인스티튜트 인크. Therapeutic peptides KR102311761B1 (en) 2013-12-09 2021-10-13 알라코스 인크. Anti-siglec-8 antibodies and methods of use thereof CN106030310B (en) 2013-12-13 2019-01-04 通用医疗公司 Soluble high-molecular amount (HMW) TAU type and its application EP3461845B1 (en) 2013-12-13 2020-09-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody RS59659B2 (en) 2013-12-17 2023-08-31 Hoffmann La Roche PD-1 AXIS BINDING ANTAGONISTS AND TAXANE-ASSISTED CANCER TREATMENTS EP3083689B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use MX2016007965A (en) 2013-12-17 2016-10-28 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists. US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA ES2778498T3 (en) 2013-12-20 2020-08-10 Hoffmann La Roche Humanized anti-tau (pS422) antibodies and procedures for use TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same DK3087098T3 (en) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista antibodies and fragments KR102452173B1 (en) 2013-12-24 2022-10-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn antagonists and methods of use RU2682754C2 (en) 2014-01-03 2019-03-21 Ф. Хоффманн-Ля Рош Аг Covalent bonded polypeptide toxin and antibody conjugates MX373856B (en) 2014-01-03 2025-03-04 Hoffmann La Roche Covalently bonded helical-antibody conjugates and their uses. WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles CN111057151B (en) 2014-01-06 2022-05-03 豪夫迈·罗氏有限公司 Monovalent BBB Shuttle Module EP4176894B1 (en) 2014-01-10 2024-02-28 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof CN105899534B (en) 2014-01-15 2020-01-07 豪夫迈·罗氏有限公司 Fc region variants with modified FCRN and maintained protein A binding properties WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof MX2016009515A (en) 2014-01-24 2016-10-26 Genentech Inc Methods of using anti-steap1 antibodies and immunoconjugates. EP3097122B9 (en) 2014-01-24 2020-11-11 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof ES2694857T3 (en) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutant and methods of using it US20150246963A1 (en) 2014-02-08 2015-09-03 Genentech, Inc. Methods of treating alzheimer's disease TWI785472B (en) 2014-02-08 2022-12-01 美商建南德克公司 Methods of treating alzheimer's disease PE20161335A1 (en) 2014-02-12 2016-12-07 Genentech Inc ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE JP6533534B2 (en) 2014-02-14 2019-06-19 マクロジェニクス，インコーポレーテッド Composition for use in the treatment of glioblastoma and use thereof CR20160379A (en) 2014-02-21 2016-10-07 Genentech Inc BISPECIFIC ANTIBODIES ANTI-IL 13 / IL-17 AND ITS USES US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics CN106659800A (en) 2014-03-12 2017-05-10 诺华股份有限公司 Specific sites for modifying antibodies to make immunoconjugates CN106456728A (en) 2014-03-14 2017-02-22 达纳－法伯癌症研究所公司 Vaccine compositions and methods for restoring NKG2D pathway function against cancers SI3116999T1 (en) 2014-03-14 2021-12-31 F. Hoffmann - La Roche Ag Methods and compositions for secretion of heterologous polypeptides US10280222B2 (en) 2014-03-14 2019-05-07 Innate Pharma Humanized antibodies with increased stability ES2788973T3 (en) 2014-03-14 2020-10-23 Biomolecular Holdings Llc Hybrid immunoglobulin containing a non-peptidyl bond TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment PL3129067T3 (en) 2014-03-19 2023-05-08 Genzyme Corporation Site-specific glycoengineering of targeting moieties WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof CA2943242A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression CN106102767B (en) 2014-03-27 2021-08-10 豪夫迈·罗氏有限公司 Methods for diagnosing and treating inflammatory bowel disease WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists BR112016022658A2 (en) 2014-03-31 2017-10-17 Genentech Inc anti-ox40 antibodies and methods of use WO2015153916A1 (en) 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5 CN106459206B (en) 2014-04-07 2024-06-07 中外制药株式会社 Immune-activating antigen binding molecules SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38 CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof AR100353A1 (en) 2014-05-08 2016-09-28 Chugai Pharmaceutical Co Ltd ADDRESS DRUG TO GLIPICANO 3 (GPC3) THAT IS MANAGED TO A PATIENT RESPONDING TO THERAPY WITH ADDRESS DRUGS TO GPC3 SG11201609370QA (en) * 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function DK3143042T3 (en) 2014-05-16 2020-08-31 Ablynx Nv IMPROVED VARIABLE IMMUNOGLOBULIN DOMAINS CA2946662A1 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates JP2017524371A (en) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド MIT biomarkers and methods of use EP3498295A1 (en) 2014-05-28 2019-06-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof KR20220025917A (en) 2014-05-29 2022-03-03 마크로제닉스, 인크. Tri-specific binding molecules and methods of use thereof DK3148581T3 (en) 2014-05-30 2020-01-13 Henlix Biotech Co Ltd ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ANTIBODIES WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof MX2016016233A (en) 2014-06-11 2017-03-31 Genentech Inc Anti-lgr5 antibodies and uses thereof. CA2951885C (en) 2014-06-11 2023-07-04 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags JP6654581B2 (en) 2014-06-26 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Anti-BRDU antibodies and methods of use AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME EP3161002A1 (en) 2014-06-27 2017-05-03 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene TWI726608B (en) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 Anti-pd-l1 antibodies and their use as therapeutics and diagnostics MX2017000419A (en) 2014-07-11 2017-08-16 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof. EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition AU2015292678B2 (en) 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates JP6909153B2 (en) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド Anti-PD-L1 antibody KR102659872B1 (en) 2014-08-07 2024-04-24 노파르티스 아게 Angiopoietin-like 4 antibodies and methods of use WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use KR20170040249A (en) 2014-08-12 2017-04-12 노파르티스 아게 Anti-cdh6 antibody drug conjugates JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments CR20170060A (en) 2014-08-19 2017-04-18 Merck Sharp & Dohme ANTI TIGIT ANTIBODIES WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease KR20230172625A (en) 2014-08-28 2023-12-22 바이오아트라, 인코퍼레이티드 Conditionally active chimeric antigen receptors for modified t-cells FR3025515B1 (en) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement PROCESS FOR PURIFYING MONOCLONAL ANTIBODY TW201617368A (en) 2014-09-05 2016-05-16 史坦森特瑞斯公司 Novel anti-MFI2 antibodies and methods of use ES2989338T3 (en) 2014-09-12 2024-11-26 Genentech Inc Anti-CLL-1 antibodies and immunoconjugates EP3191135B1 (en) 2014-09-12 2020-08-19 Genentech, Inc. Anti-her2 antibodies and immunoconjugates TW201625688A (en) 2014-09-12 2016-07-16 建南德克公司 Cysteine engineered antibodies and conjugates EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates JP6730261B2 (en) 2014-09-17 2020-07-29 ジェネンテック， インコーポレイテッド Immune complex containing anti-HER2 antibody DK3262071T3 (en) 2014-09-23 2020-06-15 Hoffmann La Roche Method of using anti-CD79b immune conjugates MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY CA2962486A1 (en) 2014-09-26 2016-03-31 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof CN107108721B (en) 2014-09-29 2021-09-07 杜克大学 Bispecific molecules comprising HIV-1 envelope targeting arms US20160108105A1 (en) * 2014-10-06 2016-04-21 Genexine, Inc. Human igg4 fc polypeptide variant MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same EP3207057A2 (en) 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use MA41480A (en) 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa ANTIBODIES BOUND TO CCR6 AND THEIR USES SG11201701388UA (en) 2014-10-23 2017-03-30 Innate Pharma Treatment of cancers using anti-nkg2a agents SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof CA2966507A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria RU2705274C2 (en) 2014-11-05 2019-11-06 Дженентек, Инк. Methods for producing double-stranded proteins in bacteria BR112017008666A2 (en) 2014-11-05 2018-01-30 Genentech, Inc. anti-fgfr2 / 3 antibodies and methods of use EP3215528B1 (en) 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof KR20170076697A (en) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 Fc-region variants with modified fcrn- and protein a-binding properties SG11201703332SA (en) 2014-11-10 2017-05-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof EP3217787B1 (en) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Animal model for nephropathy and agents for treating the same WO2016075176A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof TW202313697A (en) 2014-11-11 2023-04-01 日商中外製藥股份有限公司 Library of antigen-binding molecules including modified antibody variable region CA2967188A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists JP6681396B2 (en) 2014-11-17 2020-04-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Method of treating a tumor with a CD3XCD20 bispecific antibody JP6779876B2 (en) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド Anti-transferrin receptor antibody and how to use it EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use BR112017010498A2 (en) 2014-11-19 2017-12-26 Axon Neuroscience Se humanized tau antibodies in alzheimer's disease CN107108745B (en) 2014-11-19 2021-01-12 基因泰克公司 Antibodies against BACE1 and their use for immunotherapy of neurological diseases CN107250157B (en) 2014-11-21 2021-06-29 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions ME03806B (en) 2014-11-21 2021-04-20 Bristol Myers Squibb Co ANTIBODIES TO CD73 AND USES THEREOF US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies JP2018505911A (en) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド Identification of VSIG8 as a putative VISTA receptor and its use to produce a VISTA / VSIG8 modulator KR20170086549A (en) 2014-12-05 2017-07-26 제넨테크, 인크. ANTI-CD79b ANTIBODIES AND METHODS OF USE ES2764299T3 (en) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Human monoclonal antibodies against AXL CN107207591A (en) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 Blood-brain barrier receptor antibody and application method US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins CA2966551A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Assay and method for determining cdc eliciting antibodies PE20171111A1 (en) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd ANTIMIOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE PL3233912T3 (en) 2014-12-19 2021-12-27 Regenesance B.V. Antibodies that bind human c6 and uses thereof EA201791366A1 (en) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 MX2017007744A (en) 2014-12-23 2017-09-05 Bristol Myers Squibb Co Antibodies to tigit. JP7152156B2 (en) 2015-01-14 2022-10-12 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Treatment of cancer with anti-LAP monoclonal antibodies WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use CA2974807A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same JP2018510842A (en) 2015-02-05 2018-04-19 中外製薬株式会社 Antibodies comprising ion concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and uses thereof AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation PT3295951T (en) 2015-02-19 2020-07-21 Compugen Ltd Anti-pvrig antibodies and methods of use EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis AR103782A1 (en) 2015-02-26 2017-05-31 Genentech Inc INTEGRINE b7 ANTAGONISTS AND METHODS OF TREATMENT OF CROHN'S DISEASE EP4006051A1 (en) 2015-03-09 2022-06-01 Argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonists WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors FR3034420A1 (en) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement ANTI-CD303 MONOCLONAL ANTIBODIES KR102721595B1 (en) 2015-04-03 2024-10-23 유레카 쎄라퓨틱스, 인코포레이티드 Constructs targeting AFP peptide/MHC complexes and uses thereof AR104368A1 (en) 2015-04-03 2017-07-19 Lilly Co Eli ANTI-CD20- / ANTI-BAFF BIESPECTIFIC ANTIBODIES JP6955445B2 (en) 2015-04-07 2021-10-27 ジェネンテック， インコーポレイテッド Antigen binding complex with agonistic activity and how to use it PL3283508T3 (en) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities WO2016172551A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Methods of identifying bacteria comprising binding polypeptides EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use CN115109158A (en) 2015-05-07 2022-09-27 阿吉纳斯公司 Anti-OX40 antibodies and methods of use JP6963508B2 (en) 2015-05-11 2021-11-10 ジェネンテック， インコーポレイテッド Compositions and Methods for Treating Lupus Nephritis EP3294770B2 (en) 2015-05-12 2024-03-20 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer JP6770533B2 (en) 2015-05-22 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル A human monoclonal antibody fragment that inhibits both the catalytic activity of Cath-D and its binding to the LRP1 receptor. CA2986713A1 (en) 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use AU2016271142A1 (en) 2015-05-29 2017-11-23 Genentech, Inc. PD-L1 promoter methylation in cancer EP3708681A1 (en) 2015-05-29 2020-09-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer SI3303396T1 (en) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof IL292708B2 (en) 2015-05-30 2024-08-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them JP2018516933A (en) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド Compositions and methods for treating neurological disorders using anti-IL-34 antibodies TN2017000417A1 (en) 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof MX2017014740A (en) 2015-06-08 2018-08-15 Genentech Inc Methods of treating cancer using anti-ox40 antibodies. EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors JP2018524295A (en) 2015-06-15 2018-08-30 ジェネンテック， インコーポレイテッド Antibodies and immune complexes FI3310814T3 (en) 2015-06-16 2023-09-21 Hoffmann La Roche HUMANIZED AND AFFINITY MATURE FcRH5 ANTIBODIES AND METHODS OF USE JP2018526972A (en) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド Anti-CD3 antibody and method of use EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates AU2016280070B2 (en) 2015-06-17 2022-09-15 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes JP6846362B2 (en) 2015-06-17 2021-03-24 アラコス インコーポレイテッド Methods and Compositions for Treating Fibrous Diseases MX2017016169A (en) 2015-06-17 2018-08-15 Genentech Inc Anti-her2 antibodies and methods of use. EP3313881A1 (en) 2015-06-23 2018-05-02 Innate Pharma Multispecific nk engager proteins WO2016207273A2 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity ES2809728T3 (en) 2015-06-24 2021-03-05 Hoffmann La Roche Humanized anti-tau (pS422) antibodies and procedures for use CN114805576A (en) 2015-06-24 2022-07-29 詹森药业有限公司 Anti-VISTA Antibodies and Fragments JOP20200312A1 (en) 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use CN115505042A (en) 2015-06-26 2022-12-23 赛诺菲生物技术公司 Monoclonal anti-IL-1 RACP antibodies EP3514174B1 (en) 2015-06-29 2021-03-31 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin US20170029520A1 (en) 2015-06-29 2017-02-02 Genentech, Inc. Compositions and methods for use in organ transplantation AU2016291846B2 (en) 2015-07-13 2022-05-26 Compugen Ltd. HIDE1 Compositions and Methods RU2737637C2 (en) * 2015-07-22 2020-12-01 Инатерис Anti-tfr antibodies and use thereof in treating proliferative and inflammatory disorders EP3325010B1 (en) 2015-07-23 2023-06-21 The Regents of The University of California Antibodies to coagulation factor xia and uses thereof EP3328427B1 (en) 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function TWI762879B (en) 2015-07-30 2022-05-01 美商宏觀基因股份有限公司 Pd-1-binding molecules and methods of use thereof EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF CA3185706A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same EA202092435A3 (en) 2015-08-03 2021-06-30 Энгмаб Сарл MONOCLONAL ANTIBODIES AGAINST BCMA CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody JP6914919B2 (en) 2015-08-28 2021-08-04 ジェネンテック， インコーポレイテッド Anti-hypusine antibody and its use PE20181322A1 (en) 2015-09-01 2018-08-14 Agenus Inc ANTI-PD1 ANTIBODY AND ITS METHODS OF USE DK3344654T3 (en) 2015-09-02 2021-01-18 Immutep Sas ANTI-LAG-3 ANTIBODIES UY36889A (en) 2015-09-09 2017-04-28 Novartis Ag MOLECULES OF JOINT TO TIMICA STROMAL LYMPHOPOYETIN (TSLP) AND METHODS OF USE OF THE MOLECULES KR20180042433A (en) 2015-09-09 2018-04-25 노파르티스 아게 Use of thymus substrate lymphopoietin (TSLP) -binding antibodies and antibodies WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies BR112018002432A2 (en) 2015-09-18 2018-09-18 Chugai Pharmaceutical Co Ltd il-8 binding antibodies and uses thereof TWI703158B (en) 2015-09-18 2020-09-01 美商希佛隆公司 Antibodies that specifically bind to tl1a JP7002446B2 (en) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー CD3 binding polypeptide JP6904947B2 (en) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション Anti-OX40 antibody and its diagnostic applications SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies WO2017053906A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use DK3353210T3 (en) 2015-09-25 2025-01-06 Hoffmann La Roche Anti-TIGIT antibodies and methods of use WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor IL312251A (en) 2015-10-02 2024-06-01 Hoffmann La Roche Human anti-CD20/human transferrin receptor bispecific antibodies and methods of use LT3356411T (en) 2015-10-02 2021-09-10 F. Hoffmann-La Roche Ag BIS-SPECIFIC ANTIBODIES, SPECIFIC PD1 AND TIM3 EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies MA43018B1 (en) 2015-10-02 2021-11-30 Hoffmann La Roche Anti-pd1 antibodies and methods of use AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE KR20240107346A (en) 2015-10-06 2024-07-09 제넨테크, 인크. Method for treating multiple sclerosis MX2018004157A (en) 2015-10-07 2019-04-01 F Hoffmann ­La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor. WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis TW201722989A (en) 2015-10-23 2017-07-01 輝瑞大藥廠 Anti-IL-2 antibodies and compositions and uses thereof MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST BR112018006562A2 (en) 2015-10-29 2018-12-11 Hoffmann La Roche antibodies, nucleic acid, host cell, method for producing an antibody, conjugate and use of an antibody JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use HUE054093T2 (en) 2015-10-30 2021-08-30 Hoffmann La Roche Anti-HtrA1 antibodies and methods of their use EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof PL3368579T3 (en) 2015-10-30 2022-03-21 F. Hoffmann-La Roche Ag Hinge modified antibody fragments and methods of making TW201730211A (en) 2015-10-30 2017-09-01 建南德克公司 Anti-Factor D antibodies and conjugates CN118725134A (en) 2015-11-08 2024-10-01 豪夫迈·罗氏有限公司 Methods for screening multispecific antibodies WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response KR20180082563A (en) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 Antibodies to glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof CN108925136B (en) 2015-12-02 2022-02-01 斯特赛恩斯公司 Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor) JP7090545B2 (en) 2015-12-02 2022-06-24 ストキューブ アンド シーオー．， インコーポレイテッド Antibodies and molecules that immunospecifically bind to BTN1A1 and their therapeutic use MA43372A (en) 2015-12-04 2018-10-10 Novartis Ag CYTOKINE ANTIBODY TRANSPLANT COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION EA201891178A1 (en) 2015-12-14 2019-01-31 Макродженикс, Инк. Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use CN109069570A (en) 2015-12-16 2018-12-21 默沙东公司 Anti- LAG3 antibody and antigen-binding fragment TW202344514A (en) 2015-12-18 2023-11-16 日商中外製藥股份有限公司 Anti-c5 antibodies and methods of use EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide CN108368179B (en) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 Methods of treating CEA positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD 3 bispecific antibodies CN109069627A (en) 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 To the T cell receptor sample antibody of the derivative peptide specific of FOXP3 BR112018014762A2 (en) 2016-01-20 2018-12-26 Genentech Inc method of treating (early) alzheimer's disease PL3411478T3 (en) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Optimized factor viii genes EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same BR112018016461A2 (en) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv antibodies and anti-sight fragments, their uses and their identification methods US11180546B2 (en) 2016-02-17 2021-11-23 Novartis Ag TGFbeta 2 antibodies EP3423596B1 (en) 2016-02-29 2022-09-28 Genentech, Inc. Therapeutic and diagnostic methods for cancer BR112018067368A2 (en) 2016-03-04 2019-01-15 Bristol-Myers Squibb Company anti-cd73 antibody combination therapy SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy CN109071631B (en) 2016-03-14 2023-07-14 奥斯陆大学 Engineered immunoglobulins with altered FcRn binding SG11201806542PA (en) 2016-03-15 2018-08-30 Innate Pharma Anti-mica antibodies EP4112641A1 (en) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies US20190077870A1 (en) 2016-03-16 2019-03-14 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy KR102640157B1 (en) 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Humanized anti-claudin-1 antibodies and uses thereof JP2019509322A (en) 2016-03-22 2019-04-04 バイオノミクス リミテッド Administration of anti-LGR5 monoclonal antibody CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplex Total Antibody and Antibody Conjugated Drug Quantification Assay KR20240034883A (en) 2016-03-29 2024-03-14 얀센 바이오테크 인코포레이티드 Treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use CN117562992A (en) 2016-04-15 2024-02-20 伊穆奈克斯特股份有限公司 Anti-human VISTA antibodies and uses thereof BR112018071105A2 (en) 2016-04-15 2019-02-26 Macrogenics, Inc. drug and antibody conjugate, binding molecule, pharmaceutical composition and use EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis CN109154027A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer KR102459684B1 (en) 2016-04-15 2022-10-26 바이오아트라, 인코퍼레이티드 Anti-axl antibodies and their immunoconjugates and uses thereof EP3443000A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof MX2018012492A (en) 2016-04-15 2019-06-06 Genentech Inc Methods for monitoring and treating cancer. WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins CA3021098A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same CN109071647B (en) 2016-04-27 2022-11-22 诺华股份有限公司 Anti-growth differentiation factor 15 antibody and application thereof CR20180509A (en) 2016-05-02 2019-02-15 Hoffmann La Roche CONTORSBODY - A BIND OF DIANA MONOCATENARY EA039084B1 (en) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Tl1a antibodies and uses thereof WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use KR20180137517A (en) 2016-05-13 2018-12-27 바이오아트라, 엘엘씨 Anti-ROR2 antibodies, antibody fragments and immunoconjugates thereof and uses thereof WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use TW201802121A (en) 2016-05-25 2018-01-16 諾華公司 Reversal binding agent against factor XI/XIa antibody and use thereof SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use PT3468997T (en) 2016-06-08 2023-12-07 Debra Zack Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) TWI611811B (en) 2016-06-17 2018-01-21 中外製藥股份有限公司 Anti-myostatin antibody and method of use WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies WO2018005954A2 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods CN109415435B (en) 2016-07-04 2024-01-16 豪夫迈·罗氏有限公司 Novel antibody forms JP6993056B2 (en) 2016-07-05 2022-02-15 ベイジーン リミテッド Combination of PD-1 antagonist and RAF inhibitor for cancer treatment KR102493282B1 (en) 2016-07-14 2023-02-01 브리스톨-마이어스 스큅 컴퍼니 Antibodies to TIM3 and uses thereof JP7241677B2 (en) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Anti-CD47 combination therapy WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof WO2018017964A2 (en) 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof CN109415444B (en) 2016-07-29 2024-03-01 中外制药株式会社 Bispecific antibodies exhibiting increased functional activity of alternative FVIII cofactors NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies BR112019001693A2 (en) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse antibodies targeting tumor-associated macrophages and their uses NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies MX2019001458A (en) 2016-08-02 2019-07-04 Visterra Inc Engineered polypeptides and uses thereof. WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy CA3032437A1 (en) 2016-08-05 2018-02-08 Allakos, Inc. Anti-siglec-7 antibodies for the treatment of cancer CN109689099B (en) 2016-08-05 2023-02-28 中外制药株式会社 Composition for preventing or treating IL-8-related diseases EP3496748A4 (en) 2016-08-05 2020-01-15 Medimmune, LLC Anti-o2 antibodies and uses thereof CN109476748B (en) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 Methods for treatment and diagnosis of cancer WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof JP7178342B2 (en) * 2016-08-12 2022-11-25 ヤンセン バイオテツク，インコーポレーテツド Engineered Antibodies with Enhanced Agonism and Effector Functions, and Other Fc Domain-Containing Molecules EP3347379B9 (en) 2016-08-17 2020-03-25 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof ES2971881T3 (en) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combination of zanubrutinib with an anti-cd20 or anti-pd-1 antibody for use in cancer treatment WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof AU2017321973B2 (en) 2016-09-02 2024-09-05 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders WO2018053032A1 (en) 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis AU2017327828B2 (en) 2016-09-16 2023-11-16 Shanghai Henlius Biotech, Inc. Anti-PD-1 antibodies SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use CN116731197A (en) 2016-09-19 2023-09-12 豪夫迈·罗氏有限公司 Complement factor-based affinity chromatography JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein MX2019002867A (en) 2016-09-19 2019-11-12 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins. JP7069177B2 (en) 2016-09-21 2022-05-17 ネクストキュア インコーポレイテッド Antibodies to Siglec-15 and how to use them EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof HRP20231015T1 (en) 2016-09-23 2023-12-08 F. Hoffmann-La Roche Ag Uses of il-13 antagonists for treating atopic dermatitis JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies MA46366A (en) 2016-09-30 2019-08-07 Janssen Biotech Inc SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTIBODY AGAINST IL-23 CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4 TWI843168B (en) 2016-10-11 2024-05-21 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof MX2019004691A (en) 2016-10-20 2019-12-09 I Mab Biopharma Us Ltd Novel cd47 monoclonal antibodies and uses thereof. US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein KR20190068602A (en) 2016-10-21 2019-06-18 이나뜨 파르마 Treatment with anti-KIR3DL2 agonists WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion MX2019005438A (en) 2016-11-15 2019-08-16 Genentech Inc Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies. AU2017362222B2 (en) 2016-11-16 2024-12-05 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof JOP20190100A1 (en) 2016-11-19 2019-05-01 Potenza Therapeutics Inc Anti-gitr antigen-binding proteins and methods of use thereof AU2017361887B2 (en) 2016-11-21 2019-08-15 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates PE20200012A1 (en) 2016-11-23 2020-01-06 Bioverativ Therapeutics Inc MONO- AND BI-SPECIFIC ANTIBODIES THAT BIND TO COAGULATION FACTOR IX AND COAGULATION FACTOR X IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life PE20190921A1 (en) 2016-12-07 2019-06-26 Agenus Inc ANTIBODIES AND METHODS OF THEIR USE KR20230146126A (en) 2016-12-07 2023-10-18 제넨테크, 인크. Anti-tau antibodies and methods of use KR20240035636A (en) 2016-12-07 2024-03-15 제넨테크, 인크. Anti-tau antibodies and methods of their use MA50949B1 (en) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF KR20190095921A (en) 2016-12-12 2019-08-16 제넨테크, 인크. How to Treat Cancer Using Anti-PD-L1 Antibody and Antiandrogen SI3555132T1 (en) 2016-12-19 2024-04-30 Medimmune Limited Antibodies against lif and uses thereof WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof PL3559034T3 (en) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Combination therapy with anti-CD20 / anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists AU2017382850B2 (en) 2016-12-21 2024-11-21 Cephalon Llc Antibodies that specifically bind to human IL-15 and uses thereof JOP20190134A1 (en) 2016-12-23 2019-06-02 Potenza Therapeutics Inc Anti-neuropilin antigen-binding proteins and methods of use thereof WO2018115262A1 (en) 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins KR102616666B1 (en) 2016-12-23 2023-12-27 노파르티스 아게 Factor XI Antibodies and Methods of Use PE20191546A1 (en) 2017-01-03 2019-10-24 Hoffmann La Roche BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 20H4.9 ANTI-41BB WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof MA47236A (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics Inc TUMOR INFILTRATION LYMPHOCYTE (TIL) EXPANSION WITH TUMOR NECROSIS FACTOR (TNFRSF) SUPERFAMILY RECEPTOR AGONISTS AND THERAPEUTIC COMBINATIONS OF TIL AND TNFRSF AGONISTS JP2020503351A (en) 2017-01-06 2020-01-30 アイオバンス バイオセラピューティクス，インコーポレイテッド Proliferation of tumor infiltrating lymphocytes by potassium channel agonist and its therapeutic use TW201831517A (en) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 Construct for targeting tissue protein H3 peptide/MHC complex and use thereof WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof KR101949891B1 (en) 2017-01-31 2019-02-19 추가이 세이야쿠 가부시키가이샤 Pharmaceutical compositions for treating or preventing C5-related diseases and methods for treating or preventing C5-related diseases WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof UA128814C2 (en) * 2017-02-10 2024-10-30 Генмаб Б.В. Polypeptide variants and uses thereof EP3580240A1 (en) 2017-02-10 2019-12-18 H. Hoffnabb-La Roche Ag Anti-tryptase antibodies, compositions thereof, and uses thereof SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof UA127985C2 (en) 2017-02-17 2024-03-06 Деналі Терап'Ютікс Інк. ENGINEERED POLYPEPTIDE THAT BINDS THE TRANSFERRIN RECEPTOR CA3052837A1 (en) 2017-02-28 2018-09-07 Seattle Genetics, Inc. Cysteine mutated antibodies for conjugation CN116440257A (en) 2017-02-28 2023-07-18 百时美施贵宝公司 Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to vaccine AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof KR20240123406A (en) 2017-03-16 2024-08-13 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l1 variant immunomodulatory proteins and uses thereof CN110662758A (en) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 CD80 variant immunomodulatory proteins and uses thereof PE20191758A1 (en) 2017-03-22 2019-12-12 Genentech Inc ANTIBODY COMPOSITIONS OPTIMIZED FOR THE TREATMENT OF EYE DISORDERS US10982000B2 (en) 2017-03-24 2021-04-20 Novartis Ag Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody TWI848907B (en) 2017-03-28 2024-07-21 美商建南德克公司 Methods of treating neurodegenerative diseases EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor JP7196094B2 (en) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific Antigen Binding Molecules for Costimulatory TNF Receptors JOP20190203A1 (en) 2017-03-30 2019-09-03 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap SI3606954T1 (en) 2017-04-05 2022-10-28 F. Hoffmann - La Roche Ag Anti-lag3 antibodies MA49038B1 (en) 2017-04-05 2025-01-31 F. Hoffmann-La Roche Ag BISPECIFIC ANTIBODIES BINDING PARTICULARLY TO PD1 AND LAG3 TWI796329B (en) 2017-04-07 2023-03-21 美商默沙東有限責任公司 Anti-ilt4 antibodies and antigen-binding fragments CN110546166B (en) 2017-04-13 2024-03-29 艾吉纳斯公司 anti-CD 137 antibodies and methods of use thereof TW201839400A (en) 2017-04-14 2018-11-01 美商建南德克公司 Diagnostic and therapeutic methods for cancer KR20250017758A (en) 2017-04-14 2025-02-04 엑셀리시스, 인코포레이티드 Amhrii-binding compounds for preventing or treating lung cancers BR112019021472A8 (en) 2017-04-14 2023-05-02 Inst Curie AMHRII-BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF CANCER CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation MX2019012419A (en) 2017-04-21 2019-12-05 Genentech Inc Use of klk5 antagonists for treatment of a disease. US11447564B2 (en) 2017-04-26 2022-09-20 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof SG11201909395TA (en) 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. Methods and compositions for treating allergic ocular diseases KR20200003913A (en) 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. Expansion of Tumor Infiltrating Lymphocytes from Liquid Tumors and Uses thereof US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders WO2018218056A1 (en) 2017-05-25 2018-11-29 Birstol-Myers Squibb Company Antibodies comprising modified heavy constant regions JP7369038B2 (en) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 JP7348072B2 (en) 2017-06-01 2023-09-20 コンピュジェン リミテッド Triple combination antibody therapy KR20200026209A (en) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer PE20200013A1 (en) 2017-06-20 2020-01-06 Amgen Inc METHOD TO TREAT OR IMPROVE METABOLIC DISORDERS WITH GASTRIC INHIBITOR PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN COMBINATION WITH GLP-1 AGONISTS EP3641830A1 (en) 2017-06-23 2020-04-29 Velosbio Inc. Ror1 antibody immunoconjugates EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. Immunotherapy for hepatocellular carcinoma JP2020525421A (en) 2017-06-28 2020-08-27 ノバルティス アーゲー Methods for preventing and treating urinary incontinence CN111492245A (en) 2017-07-21 2020-08-04 基因泰克公司 Methods of treatment and diagnosis of cancer CN107748262A (en) * 2017-07-26 2018-03-02 东曜药业有限公司 A kind of ELISA detection method of Fc γ RIIIA acceptors CN107748258A (en) * 2017-07-26 2018-03-02 东曜药业有限公司 A kind of ELISA detection method of Fc γ RII acceptors CN107748253A (en) * 2017-07-26 2018-03-02 东曜药业有限公司 A kind of ELISA detection method of Fc γ RI acceptors CN107748259A (en) * 2017-07-26 2018-03-02 东曜药业有限公司 A kind of ELISA detection method of FcRn acceptors CN111448210B (en) 2017-07-26 2024-05-14 四十七公司 Anti-SIRP-α antibodies and related methods ES2965486T3 (en) 2017-07-27 2024-04-15 Alexion Pharma Inc High concentration anti-C5 antibody formulations AU2018313921B2 (en) 2017-08-09 2024-12-19 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof CA3070297A1 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof MX2020002070A (en) 2017-08-22 2020-03-24 Sanabio Llc Soluble interferon receptors and uses thereof. CN119552248A (en) 2017-08-25 2025-03-04 戊瑞治疗有限公司 B7-H4 antibodies and methods of use thereof EP3456737B1 (en) 2017-09-19 2024-02-14 Tillotts Pharma Ag Antibody variants EP3456736B1 (en) 2017-09-19 2021-04-07 Tillotts Pharma Ag Antibody variants EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method for treating lupus with anti-IL12/IL23 antibody MY204641A (en) 2017-09-29 2024-09-06 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof CN111801347A (en) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 CTLA-4 variant immunomodulatory proteins and uses thereof JP2020536967A (en) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド VEGFR-antibody light chain fusion protein BR112020007309A2 (en) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. antibodies, activable antibodies, bispecific antibodies and bispecific activable antibodies and methods of using them SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods AU2018353420A1 (en) 2017-10-20 2020-04-16 F. Hoffmann-La Roche Ag Method for generating multispecific antibodies from monospecific antibodies EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof AU2018354404A1 (en) 2017-10-26 2020-04-16 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) CN111372947A (en) 2017-10-30 2020-07-03 豪夫迈·罗氏有限公司 Methods of producing multispecific antibodies from monospecific antibodies in vivo CA3077664A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer CA3081854A1 (en) 2017-11-08 2019-05-16 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to cd40 and epcam US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use CA3079363A1 (en) 2017-11-21 2019-05-31 Innate Pharma Multispecific antigen binding proteins JP2021503891A (en) 2017-11-22 2021-02-15 ノバルティス アーゲー Reversal binders for anti-factor XI / XIa antibodies and their use CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood CN111801334B (en) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors CA3083363A1 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody CA3085765A1 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules TW201929907A (en) 2017-12-22 2019-08-01 美商建南德克公司 Use of PILRA binding agents for treatment of a Disease TWI817974B (en) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 Cytotoxicity-inducing therapeutic agent WO2019129211A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1 JP7369127B2 (en) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Single domain antibodies against TIGIT and variants thereof CN111511400A (en) 2017-12-29 2020-08-07 豪夫迈·罗氏有限公司 anti-VEGF antibodies and methods of use thereof FR3076294B1 (en) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement METHOD FOR PURIFYING ANTIBODIES FROM RAW MILK AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof IL315325A (en) 2018-01-04 2024-10-01 Iconic Therapeutics Inc Anti-tissue-mediated antibodies, antibody-drug conjugates, and related methods SG11202006348VA (en) 2018-01-05 2020-07-29 Ac Immune Sa Misfolded tdp-43 binding molecules EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof SG11202004233UA (en) 2018-01-15 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against pd-1 EP3740505A1 (en) 2018-01-16 2020-11-25 Lakepharma Inc. Bispecific antibody that binds cd3 and another target BR112020013420A2 (en) 2018-01-26 2020-12-01 Genentech, Inc. compositions, methods to treat disease, to inhibit infection, to treat injury, to speed up or improve healing, to prevent or treat a condition, to treat syndrome, to treat endotoxemia, to produce a composition, to select a batch, to control the content of acid and use AU2019212703A1 (en) 2018-01-26 2020-08-13 Genentech, Inc. Compositions and methods of use EP3743441A1 (en) * 2018-01-26 2020-12-02 Genzyme Corporation Fc variants with enhanced binding to fcrn and prolonged half-life WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies CN111918674A (en) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 Use of lentiviral vectors expressing factor VIII WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use CA3088557C (en) 2018-02-09 2024-02-27 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists US11591399B2 (en) 2018-02-14 2023-02-28 Abba Therapeutics Ag Anti-human PD-L2 antibodies KR20200123118A (en) 2018-02-21 2020-10-28 제넨테크, 인크. Dosing for treatment with IL-22 Fc fusion protein AU2019225249A1 (en) 2018-02-26 2020-09-17 Genentech, Inc. Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders EA202091810A1 (en) 2018-03-02 2021-01-29 Файв Прайм Терапьютикс, Инк. ANTIBODIES TO B7-H4 AND METHODS OF THEIR APPLICATION WO2019171252A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody CA3092002A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use EP3765522A4 (en) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use KR20200135421A (en) 2018-03-21 2020-12-02 파이브 프라임 테라퓨틱스, 인크. Antibodies that bind to VISTA at acidic pH EP3768315A4 (en) * 2018-03-21 2022-11-30 Dana Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof MX2020009861A (en) 2018-03-23 2020-10-08 Bristol Myers Squibb Co Antibodies against mica and/or micb and uses thereof. CA3094112A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use SG11202009542PA (en) 2018-03-29 2020-10-29 Genentech Inc Modulating lactogenic activity in mammalian cells JP7346790B2 (en) 2018-03-30 2023-09-20 ナンジン レジェンド バイオテック カンパニー，リミテッド Single domain antibodies against LAG-3 and their uses JOP20200240A1 (en) 2018-04-02 2020-09-27 Bristol Myers Squibb Co Anti-trem-1 antibodies and uses thereof reference to sequence listing submitted electronically via efs-web TW202011029A (en) 2018-04-04 2020-03-16 美商建南德克公司 Methods for detecting and quantifying FGF21 EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer KR20210021287A (en) 2018-04-12 2021-02-25 메디뮨 리미티드 Combination of LIF inhibitor and PD-1 axis inhibitor for use in treating cancer CR20200550A (en) 2018-04-13 2020-12-15 Genentech Inc Stable anti-cd79b immunoconjugate formulations AR115052A1 (en) 2018-04-18 2020-11-25 Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM US11958895B2 (en) 2018-05-03 2024-04-16 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof CN110464842B (en) 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 Formulations comprising anti-PCSK 9 antibodies and uses thereof MA52590A (en) 2018-05-11 2021-03-17 Janssen Biotech Inc METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES KR20210008514A (en) 2018-05-14 2021-01-22 메디뮨 리미티드 Antibodies to LIF and dosage forms thereof KR20210013091A (en) 2018-05-16 2021-02-03 시에스엘 리미티드 Soluble complement receptor type 1 variant and uses thereof MX2020012397A (en) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Methods of treating hemophilia a. WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use SG11202011024WA (en) 2018-05-23 2020-12-30 Beigene Ltd Anti-ox40 antibodies and methods of use UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES CN112165974B (en) 2018-05-31 2024-11-08 诺华股份有限公司 Hepatitis B Antibody EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof CA3101019A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use US20210238308A1 (en) 2018-06-04 2021-08-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function MA52783A (en) 2018-06-05 2021-04-14 Amgen Inc ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS MODULATION TWI851577B (en) 2018-06-07 2024-08-11 美商思進公司 Camptothecin conjugates CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia TWI848953B (en) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 Multi-specific binding proteins for cancer treatment WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof WO2019243900A2 (en) 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer CN112469440B (en) 2018-06-18 2024-09-06 优瑞科生物技术公司 Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof WO2019246404A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof CN112585166A (en) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 Methods of treating lung cancer with PD-1 axis binding antagonists, platinating agents, and topoisomerase II inhibitors CN114903978A (en) 2018-07-03 2022-08-16 百时美施贵宝公司 FGF-21 formulations TW202035447A (en) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 Novel bispecific agonistic 4-1bb antigen binding molecules EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4 WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof BR112021000303A2 (en) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. ANTIBODIES THAT BIND THE SIGHT IN ACID PH US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody MX2021000558A (en) 2018-07-18 2021-04-13 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent. KR20200033348A (en) 2018-08-01 2020-03-27 추가이 세이야쿠 가부시키가이샤 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease MX2021000827A (en) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other. JP7602454B2 (en) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic Acid Molecules and Their Use for Non-Viral Gene Therapy - Patent application CA3051549A1 (en) 2018-08-09 2020-02-09 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha Anti-cd137 antigen-binding molecule and utilization thereof CN112584863A (en) 2018-08-17 2021-03-30 Ab工作室有限公司 Catalytic antibodies and methods of use thereof MA53495A (en) 2018-08-31 2021-12-08 Regeneron Pharma DOSING STRATEGY TO MITIGATE CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents AU2019337759A1 (en) 2018-09-10 2021-03-11 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies MX2021002792A (en) 2018-09-11 2021-05-12 Amgen Inc Methods of modulating antibody-dependent cell-mediated cytotoxicity. JP7534303B2 (en) 2018-09-13 2024-08-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Novel LILRB4 Antibodies and Uses Thereof JP2022502076A (en) 2018-09-18 2022-01-11 メリマック ファーマシューティカルズ インコーポレーティッド Anti-TNFR2 antibody and its use US20220177587A1 (en) 2018-09-19 2022-06-09 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs KR20210063330A (en) 2018-09-19 2021-06-01 제넨테크, 인크. Methods of treatment and diagnosis for bladder cancer MX2021003213A (en) 2018-09-21 2021-05-12 Genentech Inc Diagnostic methods for triple-negative breast cancer. FI13575Y1 (en) 2018-09-24 2024-03-26 Janssen Biotech Inc IL12/IL23 antibody to be used in a safe and efficient method for treating ulcerative colitis AU2019349651B2 (en) 2018-09-27 2023-12-07 Celgene Corporation SIRP alpha binding proteins and methods of use thereof US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides KR20210068061A (en) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule comprising a modified antibody variable region AU2019347412A1 (en) 2018-09-28 2021-05-27 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously JP2022511396A (en) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antigen-binding molecule with trivalent binding to CD40 CN112955468B (en) 2018-10-01 2024-08-09 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules comprising anti-FAP clone 212 TW202035445A (en) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 Anti-lap antibody variants and uses thereof UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins MX2021004348A (en) 2018-10-18 2021-05-28 Genentech Inc Diagnostic and therapeutic methods for sarcomatoid kidney cancer. CN112996561A (en) 2018-10-30 2021-06-18 亚力兄制药公司 Subcutaneous dosage and administration of anti-C5 antibody for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates JP2022524175A (en) 2018-11-02 2022-04-28 オクラホマ メディカル リサーチ ファウンデーション Monoclonal antibody against ELTD1 and its use JP7620546B2 (en) 2018-11-05 2025-01-23 ジェネンテック， インコーポレイテッド Method for producing two-chain proteins in prokaryotic host cells KR20210091212A (en) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies JP7627216B2 (en) 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター Antibodies to mucin-16 and methods of using same - Patents.com JP2022513094A (en) 2018-11-20 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド A safe and effective way to treat psoriasis with anti-IL-23 specific antibodies WO2020104705A2 (en) 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease CN112334483B (en) 2018-11-27 2022-05-10 信达生物制药(苏州)有限公司 anti-IL-23 p19 antibodies and uses thereof CN113348177A (en) 2018-11-28 2021-09-03 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof KR20210100656A (en) 2018-12-05 2021-08-17 제넨테크, 인크. Diagnostic methods and compositions for cancer immunotherapy EP3891186A1 (en) 2018-12-05 2021-10-13 MorphoSys AG Multispecific antigen-binding molecules JP7536294B2 (en) 2018-12-05 2024-08-20 株式会社バイカ・セラピュティクス Fc region variants of antibodies CA3119798A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody US20220098310A1 (en) 2018-12-06 2022-03-31 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins JP2022513228A (en) 2018-12-14 2022-02-07 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Anti-periostin antibody and its use JP2022514867A (en) 2018-12-18 2022-02-16 カタパルト セラピューティクス ビー．ヴイ． Use of anti-CCR7 MAB for the prevention or treatment of graft-versus-host disease (GvHD) US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody TW202039554A (en) 2018-12-19 2020-11-01 瑞士商諾華公司 Anti-tnf-alpha antibodies JP2022514290A (en) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド Modified antibody FC and usage US11130804B2 (en) 2018-12-21 2021-09-28 Hoffmann-La Roche Inc. Antibody that binds to VEGF and IL-1beta and methods of use TWI851632B (en) 2018-12-21 2024-08-11 美商建南德克公司 Methods of producing polypeptides using a cell line resistant to apoptosis SG11202106498XA (en) 2018-12-26 2021-07-29 Xilio Development Inc Anti-ctla4 antibodies and methods of use thereof EP3902824A4 (en) 2018-12-28 2023-01-04 Sparx Therapeutics Inc. Binding molecules specific for claudin 18.2, compositons and methods thereof, for treatment of cancer and other diseases MX2021007797A (en) 2018-12-28 2021-10-26 Kyowa Kirin Co Ltd BISPECIFIC ANTIBODY BINDING TO TfR. JP7650802B2 (en) 2018-12-30 2025-03-25 エフ． ホフマン－ラ ロシュ アーゲー Anti-rabbit CD19 antibodies and methods of use SG11202106686PA (en) 2019-01-04 2021-07-29 Resolve Therapeutics Llc Treatment of sjogren's disease with nuclease fusion proteins CN113710702A (en) 2019-01-14 2021-11-26 健泰科生物技术公司 Methods of treating cancer with PD-1 axis binding antagonists and RNA vaccines WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2 CA3125945A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma AU2020211974A1 (en) 2019-01-22 2021-08-05 Genentech, Inc. Immunoglobulin a antibodies and methods of production and use BR112021014106A2 (en) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF AU2020211728A1 (en) 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof JP2022523475A (en) 2019-01-23 2022-04-25 ジェネンテック， インコーポレイテッド How to produce multimeric proteins in eukaryotic host cells JP2022518282A (en) 2019-01-23 2022-03-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Anti-CD38 binding domain CN113329770A (en) 2019-01-24 2021-08-31 中外制药株式会社 Novel cancer antigen and antibody against said antigen GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents CA3130695A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies CN113748202B (en) 2019-03-01 2024-07-16 艾欧凡斯生物治疗公司 Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof WO2020180712A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof KR20210138588A (en) 2019-03-08 2021-11-19 제넨테크, 인크. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles TW202100556A (en) 2019-03-14 2021-01-01 美商建南德克公司 Treatment with her2 t cell-dependent bispecific antibodies WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions KR20210141583A (en) 2019-03-18 2021-11-23 얀센 바이오테크 인코포레이티드 Methods of Treating Psoriasis in Children Using Anti-IL-12/IL-23 Antibodies US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain CN113631573B (en) 2019-03-25 2024-06-04 国家医疗保健研究所 Anti-Tau antibodies and their use in preparing drugs for treating diseases US20220153840A1 (en) 2019-04-03 2022-05-19 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation CA3136488A1 (en) 2019-04-08 2020-10-15 Biogen Ma Inc. Anti-integrin antibodies and uses thereof GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies WO2020214606A1 (en) * 2019-04-15 2020-10-22 The Medical College Of Wisconsin, Inc. Recombinant pd-l1 peptides and methods of use CA3136816A1 (en) 2019-04-17 2020-10-22 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins KR20210154179A (en) 2019-04-18 2021-12-20 에이씨 이뮨 에스.에이. Novel molecules for therapeutic and diagnostic use CN113924118A (en) 2019-04-18 2022-01-11 百时美施贵宝公司 Ipilimumab variants with enhanced binding specificity at low pH AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use SG11202111345PA (en) 2019-04-19 2021-11-29 Chugai Pharmaceutical Co Ltd Chimeric receptor that recognizes engineered site in antibody WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody BR112021022815A2 (en) 2019-05-14 2021-12-28 Genentech Inc Methods to treat follicular lymphoma, kits, immunoconjugates and polatuzumab vedotin US20220220216A1 (en) 2019-05-15 2022-07-14 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and gpc3 JPWO2020230899A1 (en) 2019-05-15 2020-11-19 CN119613486A (en) 2019-05-20 2025-03-14 诺华股份有限公司 Antibody drug conjugates with linkers comprising hydrophilic groups EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof US20220396631A1 (en) 2019-05-21 2022-12-15 Lu HUANG Trispecific binding molecules against bcma and uses thereof WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof SG11202112453TA (en) 2019-05-23 2021-12-30 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof AU2020288499A1 (en) 2019-06-05 2022-01-27 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule PH12021552847A1 (en) 2019-06-07 2023-01-16 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION EP3981429A4 (en) 2019-06-10 2023-07-26 Chugai Seiyaku Kabushiki Kaisha ANTI-T-CELL ANTIGEN-BINDING MOLECULE FOR USE IN COMBINATION WITH A CYTOKINE INHIBITOR US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them JP7359864B2 (en) 2019-07-10 2023-10-11 中外製薬株式会社 Claudin-6 binding molecules and their uses WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies US20220267452A1 (en) 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor US20220332817A1 (en) 2019-07-15 2022-10-20 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof CN114174536A (en) 2019-07-15 2022-03-11 百时美施贵宝公司 anti-TREM-1 antibodies and uses thereof KR20220034807A (en) 2019-07-16 2022-03-18 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Antibodies having specificity for CD38 and uses thereof EP4004044A1 (en) 2019-07-24 2022-06-01 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof EP4004037A1 (en) 2019-07-26 2022-06-01 Vanderbilt University Human monoclonal antibodies to enterovirus d68 CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants MX2022001146A (en) 2019-07-29 2022-03-17 Compugen Ltd Anti-pvrig antibodies formulations and uses thereof. US20220275070A1 (en) 2019-07-31 2022-09-01 Hoffmann-La Roche Inc. Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab WO2021019033A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab BR112022002236A2 (en) 2019-08-06 2022-05-03 Glaxosmithkline Ip Dev Ltd Compositions, pharmaceutical compositions and use thereof to treat cancer, as well as formulations comprising the same JP7181438B2 (en) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド Antibodies that bind to pathological tau species and uses thereof BR112022002761A2 (en) 2019-08-12 2022-08-09 Aptevo Res & Development Llc 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, 4-1BB ANTIBODIES, OX40 ANTIBODIES CA3147677A1 (en) 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists KR20220053007A (en) 2019-08-30 2022-04-28 아게누스 인코포레이티드 Anti-CD96 antibodies and methods of use thereof JP2022547577A (en) 2019-09-12 2022-11-14 ジェネンテック， インコーポレイテッド Compositions and methods for treating lupus nephritis JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy KR20220064980A (en) 2019-09-18 2022-05-19 제넨테크, 인크. Anti-KLK7 Antibodies, Anti-KLK5 Antibodies, Multispecific Anti-KLK5/KLK7 Antibodies, and Methods of Use TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph JP2022549218A (en) 2019-09-20 2022-11-24 ジェネンテック， インコーポレイテッド Anti-tryptase antibody medication CN114729045A (en) 2019-09-26 2022-07-08 斯特库比公司 Antibodies specific for glycosylated CTLA-4 and methods of using the same WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof US11760801B2 (en) 2019-09-27 2023-09-19 Janssen Biotech, Inc. Anti-CEACAM antibodies and uses thereof CN114450304B (en) 2019-09-27 2023-12-12 国家医疗保健研究所 anti-Mullera tube inhibiting substance antibodies and uses thereof PE20221110A1 (en) 2019-09-27 2022-07-11 Genentech Inc DOSE ADMINISTRATION FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES EP4038182A1 (en) 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations CN114502595A (en) 2019-10-08 2022-05-13 奈克汀治疗有限公司 Antibodies against poliovirus receptor (PVR) and uses thereof WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof JP7413519B2 (en) 2019-10-18 2024-01-15 ジェネンテック， インコーポレイテッド Methods of using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma US20220378742A1 (en) 2019-11-04 2022-12-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies KR20220092580A (en) 2019-11-06 2022-07-01 제넨테크, 인크. Diagnosis and treatment methods for the treatment of blood cancer JP2023504699A (en) 2019-12-04 2023-02-06 エイシー イミューン ソシエテ アノニム Novel molecules for therapy and diagnosis WO2021110873A1 (en) 2019-12-04 2021-06-10 Medimmune Limited Antibodies against lif and uses thereof WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof JP2023506452A (en) 2019-12-13 2023-02-16 キュージーン インコーポレイテッド Novel interleukin-15 (IL-15) fusion proteins and uses thereof BR112022011357A2 (en) 2019-12-13 2022-08-23 Genentech Inc ISOLATED ANTIBODIES, ONE OR MORE ISOLATED NUCLEIC ACIDS, ONE OR MORE VECTORS, ONE OR MORE HOST CELLS, COMPOSITION, KIT, ANTIBODY USE, METHODS TO PRODUCE THE ANTIBODY AND METHOD TO TREAT OR DELAY PROGRESSION OF A LY6G6D POSITIVE CANCER CN113045655A (en) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 anti-OX 40 antibodies and uses thereof UA128549C2 (en) 2019-12-27 2024-08-07 Чугаі Сейяку Кабусікі Кайся ANTIBODY TO CTLA-4 AND ITS USES IL294330A (en) 2020-01-06 2022-08-01 Vaccinex Inc Anti-ccr8 antibodies and their uses WO2021140202A1 (en) 2020-01-08 2021-07-15 argenx BV Methods for treating pemphigus disorders CN110818795B (en) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 anti-TIGIT antibodies and methods of use WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine JP2023514152A (en) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー IL-10 and its uses AU2021220847A1 (en) 2020-02-11 2022-09-01 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment TW202140561A (en) 2020-02-14 2021-11-01 日商協和麒麟股份有限公司 Bispecific antibody that binds to CD3 WO2021173844A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies WO2021170067A1 (en) 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 Anti-cd137 construct and use thereof KR20220145859A (en) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. Anti-CD137 constructs, multispecific antibodies and uses thereof EP4110404A1 (en) 2020-02-28 2023-01-04 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation BR112022016720A2 (en) 2020-03-06 2022-11-16 Ona Therapeutics S L ANTI-CD36 ANTIBODIES AND THEIR USE FOR CANCER TREATMENT JP2023517345A (en) 2020-03-13 2023-04-25 ジェネンテック， インコーポレイテッド Anti-interleukin-33 antibody and uses thereof WO2021180205A1 (en) 2020-03-13 2021-09-16 江苏恒瑞医药股份有限公司 Pvrig binding protein and its medical uses PH12022552326A1 (en) 2020-03-19 2023-11-29 Genentech Inc Isoform-selective anti-tgf-beta antibodies and methods of use US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof CN115916820A (en) 2020-03-23 2023-04-04 基因泰克公司 Methods of treating pneumonia, including COVID-19 pneumonia, with IL6 antagonists JP2023518812A (en) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Combination of tocilizumab and remdesivir to treat COVID19 pneumonia WO2021194861A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia CN115867649A (en) 2020-03-24 2023-03-28 基因泰克公司 TIE2 binding agents and methods of use thereof TW202202620A (en) 2020-03-26 2022-01-16 美商建南德克公司 Modified mammalian cells FI4045533T3 (en) 2020-03-26 2024-02-02 Univ Vanderbilt Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) CN116249549A (en) 2020-03-27 2023-06-09 诺华股份有限公司 Bispecific combination therapies for the treatment of proliferative diseases and autoimmune disorders EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use AU2021250186A1 (en) 2020-03-31 2022-12-01 Chugai Seiyaku Kabushiki Kaisha DLL3-targeting multispecific antigen-binding molecules and uses thereof US20230121511A1 (en) 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules AR121706A1 (en) 2020-04-01 2022-06-29 Hoffmann La Roche OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome BR112022020742A2 (en) 2020-04-17 2022-12-20 Hutchison Medipharma Ltd ANTI-OX40 ANTIBODY AND USES OF THE SAME AU2021259861A1 (en) 2020-04-24 2022-11-17 Genentech, Inc. Methods of using anti-CD79b immunoconjugates BR112022021203A2 (en) 2020-04-24 2022-12-06 Hoffmann La Roche ENZYME MODULATION AND PATHWAY WITH SULPHYDRYL COMPOUNDS AND THEIR DERIVATIVES KR20230004520A (en) 2020-04-27 2023-01-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Isotype-independent antibodies to lipoproteins (a) EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy EP3921034A2 (en) 2020-04-28 2021-12-15 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof TW202200212A (en) 2020-05-03 2022-01-01 中國大陸商聯寧（蘇州）生物製藥有限公司 Antibody-drug conjugates comprising an anti-trop-2 antibody CN115812077A (en) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp CN115697491A (en) 2020-05-17 2023-02-03 阿斯利康(英国)有限公司 SARS-COV-2 antibodies and methods of selection and use thereof GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions CA3174236A1 (en) 2020-05-22 2021-11-25 Alwin REITER Ace2-fc fusion proteins and uses thereof EP4157881A4 (en) 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof BR112022024629A2 (en) 2020-06-02 2023-02-23 Dynamicure Biotechnology Llc ANTI-CD93 CONSTRUCTS AND THEIR USES CN116529260A (en) 2020-06-02 2023-08-01 当康生物技术有限责任公司 anti-CD 93 constructs and uses thereof AR122569A1 (en) 2020-06-08 2022-09-21 Hoffmann La Roche ANTI-HBV ANTIBODIES AND METHODS OF USE WO2021251438A1 (en) 2020-06-10 2021-12-16 株式会社バイカ・セラピュティクス Fusion protein containing erythropoietin polypeptide WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and compositions for treating triple-negative breast cancer AU2021293507A1 (en) 2020-06-18 2023-02-02 F. Hoffmann-La Roche Ag Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists TW202214286A (en) 2020-06-19 2022-04-16 日商中外製藥股份有限公司 Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor EP4169948A4 (en) 2020-06-22 2024-07-10 Innovent Biologics (Suzhou) Co., Ltd. ANTI-CD73 ANTIBODIES AND ITS USE CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein WO2021262783A1 (en) 2020-06-24 2021-12-30 Genentech, Inc. Apoptosis resistant cell lines EP4171633A1 (en) 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413 CA3187283A1 (en) 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins KR20230038735A (en) 2020-07-17 2023-03-21 제넨테크, 인크. Anti-NOTCH2 Antibodies and Methods of Use GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds KR20230133832A (en) 2020-07-29 2023-09-19 다이내믹큐어 바이오테크놀로지 엘엘씨 Anti-CD93 constructs and uses thereof WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody MX2023001120A (en) 2020-07-31 2023-02-22 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION THAT COMPRISES A CELL THAT EXPRESSES A CHIMERIC RECEPTOR. EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma WO2022031978A1 (en) 2020-08-06 2022-02-10 Bioverativ Usa Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease EP4192860A1 (en) 2020-08-10 2023-06-14 AstraZeneca UK Limited Sars-cov-2 antibodies for treatment and prevention of covid-19 TW202221026A (en) 2020-08-14 2022-06-01 瑞士商Ａｃ 免疫有限公司 Humanized anti-TDP-43 binding molecules and uses thereof KR20230048439A (en) 2020-08-18 2023-04-11 세파론 엘엘씨 Anti-PAR-2 Antibodies and Methods of Using The Same WO2022040470A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers AU2021329371A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers MX2023002017A (en) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERS. WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation CN116648507A (en) 2020-08-28 2023-08-25 基因泰克公司 CRISPR/Cas9 multiple knockout of host cell proteins US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents US20230416371A1 (en) * 2020-08-28 2023-12-28 Chugai Seiyaku Kabushiki Kaisha Heterodimer fc polypeptide EP4208201A1 (en) 2020-09-04 2023-07-12 F. Hoffmann-La Roche AG Antibody that binds to vegf-a and ang2 and methods of use JP2023541921A (en) 2020-09-17 2023-10-04 ジェネンテック， インコーポレイテッド Results of a randomized, double-blind, placebo-controlled, multicenter trial (EMPACTA) to assess the efficacy and safety of tocilizumab in hospitalized patients with COVID-19 pneumonia WO2022069940A1 (en) 2020-09-30 2022-04-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies KR20230082632A (en) 2020-10-05 2023-06-08 제넨테크, 인크. Dosing for Treatment with Anti-FCRH5/Anti-CD3 Bispecific Antibodies WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis EP4232475A1 (en) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof AU2021363766A1 (en) 2020-10-22 2023-06-15 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses EP4232822A2 (en) 2020-10-26 2023-08-30 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists CA3193930A1 (en) 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof TW202227481A (en) 2020-11-04 2022-07-16 美國洛克菲勒大學 Neutralizing anti-sars-cov-2 antibodies WO2022098648A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates WO2022098628A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies EP4240492A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof EP4240494A1 (en) 2020-11-06 2023-09-13 Novartis AG Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies CA3200314A1 (en) 2020-12-01 2022-06-09 Peter Pavlik Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods TW202237639A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof MX2023007133A (en) 2020-12-17 2023-06-27 Hoffmann La Roche Anti-hla-g antibodies and use thereof. EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes EP4262811A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof US20240043540A1 (en) 2020-12-23 2024-02-08 Innovent Biologics (Singapore) Pte. Ltd. Anti-b7-h3 antibody and uses thereof JP2024501845A (en) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド Devices and processes for automated production of tumor-infiltrating lymphocytes MX2023007846A (en) 2021-01-06 2023-07-07 Hoffmann La Roche Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody. US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies CN117083297A (en) 2021-01-22 2023-11-17 艾佩斯瑞生物制药公司 anti-PD-L1 monoclonal antibodies and fusion proteins with interleukin-15 (IL-15), interleukin-15 receptor 15 alpha or interleukin-2 WO2022165275A2 (en) 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies CN117120084A (en) 2021-01-28 2023-11-24 维肯芬特有限责任公司 Methods and means for modulating B cell mediated immune responses WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses US20240082397A1 (en) 2021-01-28 2024-03-14 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof WO2022162201A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses US20240307437A1 (en) 2021-01-29 2024-09-19 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating TGF-B signaling AR124895A1 (en) 2021-02-17 2023-05-17 Prometheus Biosciences Inc ANTI-CD30L ANTIBODIES AND THEIR USES TW202317612A (en) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 Combination of ctla4 and pd1/pdl1 antibodies for treating cancer US20220340662A1 (en) 2021-03-01 2022-10-27 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer WO2022184854A2 (en) 2021-03-03 2022-09-09 Formycon Ag Formulations of ace2 fc fusion proteins EP4301418A1 (en) 2021-03-03 2024-01-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody EP4301138A2 (en) 2021-03-05 2024-01-10 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions TW202302646A (en) 2021-03-05 2023-01-16 美商當康生物科技有限公司 Anti-vista constructs and uses thereof KR20230148226A (en) 2021-03-10 2023-10-24 이뮤노웨이크 인크. Immunomodulatory Molecules and Their Uses AR125074A1 (en) 2021-03-12 2023-06-07 Genentech Inc ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE JP2024510588A (en) 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド Method of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL23-specific antibodies EP4305061A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody TW202300521A (en) 2021-03-15 2023-01-01 美商建南德克公司 Compositions and methods of treating lupus nephritis WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents JP2024510505A (en) 2021-03-19 2024-03-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Methods for tumor-infiltrating lymphocyte (TIL) expansion and gene knockout in TILs associated with CD39/CD69 selection CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy KR20240032711A (en) 2021-03-25 2024-03-12 이오반스 바이오테라퓨틱스, 인크. Methods and compositions for use in T-cell co-culture efficacy assays and cell therapeutics TW202300648A (en) 2021-03-25 2023-01-01 美商當康生物科技有限公司 Anti-igfbp7 constructs and uses thereof MX2023011310A (en) 2021-03-26 2023-10-05 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging. WO2022201122A1 (en) 2021-03-26 2022-09-29 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof JP2024513837A (en) 2021-03-31 2024-03-27 バイオベラティブ・ユーエスエイ・インコーポレイテッド Reducing surgery-related hemolysis in patients with cold agglutinin disease EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies IL307501A (en) 2021-04-19 2023-12-01 Hoffmann La Roche Modified mammalian cells US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof AU2022269139A1 (en) 2021-05-07 2023-11-16 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2 US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy WO2022245859A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea JP2024521107A (en) 2021-05-21 2024-05-28 ジェネンテック， インコーポレイテッド Modified cells for producing recombinant products of interest WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer EP4347647A1 (en) 2021-06-01 2024-04-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of b cell depleting agents for the treatment of rheumatic heart disease TW202306994A (en) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 Anti-ddr2 antibodies and uses thereof WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a JP2024521408A (en) 2021-06-09 2024-05-31 イナート・ファルマ・ソシエテ・アノニム Multispecific antibodies binding to CD20, NKP46, CD16 and conjugated to IL-2 WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a WO2022258662A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a JP2024522175A (en) 2021-06-11 2024-06-11 ジェネンテック， インコーポレイテッド Method for treating chronic obstructive pulmonary disease with ST2 antagonists IL309349A (en) 2021-06-14 2024-02-01 argenx BV Anti-il-9 antibodies and methods of use thereof WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof IL308134A (en) 2021-06-22 2023-12-01 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa MX2023014453A (en) 2021-06-25 2024-01-31 Chugai Pharmaceutical Co Ltd Use of anti-ctla-4 antibody. WO2022270611A1 (en) 2021-06-25 2022-12-29 中外製薬株式会社 Anti–ctla-4 antibody WO2023275621A1 (en) 2021-07-01 2023-01-05 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer US20250011448A1 (en) 2021-07-08 2025-01-09 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof AU2022306973A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions EP4370545A1 (en) 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding US20240343817A1 (en) 2021-07-14 2024-10-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof JP2024527606A (en) 2021-07-14 2024-07-25 ジェネンテック， インコーポレイテッド Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof EP4373270A2 (en) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments JP2024528631A (en) 2021-07-22 2024-07-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Heterodimeric Fc domain antibodies EP4377338A2 (en) 2021-07-27 2024-06-05 Novab, Inc. Engineered vlrb antibodies with immune effector functions CN117715936A (en) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 Methods and compositions for treating cancer EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors KR20240042476A (en) 2021-07-30 2024-04-02 오엔에이 테라퓨틱스 에스.엘. Anti-CD36 antibodies and their use to treat cancer WO2023011338A1 (en) 2021-08-02 2023-02-09 信达生物制药(苏州)有限公司 Anti-cd79b×cd3 bispecific antibody and use thereof JP2024528217A (en) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibodies and methods of use KR20240040786A (en) 2021-08-03 2024-03-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Biopharmaceutical compositions and stable isotope labeled peptide mapping methods US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma CN117897409A (en) 2021-08-13 2024-04-16 基因泰克公司 Administration of anti-tryptase antibodies WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use AU2022332728A1 (en) 2021-08-26 2024-03-14 Kyowa Kirin Co., Ltd. Bispecific antibody that binds to cd116 and cd131 IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods of treating tau pathologies EP4396236A1 (en) 2021-08-30 2024-07-10 Lassen Therapeutics 1, Inc. Anti-il-11r alpha antibodies JP2024534853A (en) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド Anti-polybiquitin multispecific antibody IL311333A (en) 2021-09-09 2024-05-01 Iovance Biotherapeutics Inc Processes for the production of TIL products using a strong PD-1 TALEN KR20230042638A (en) * 2021-09-17 2023-03-29 고려대학교 산학협력단 Glycosylated Fc variants with improved selectively binding to Fc gamma receptor IIIa WO2023043124A1 (en) * 2021-09-17 2023-03-23 고려대학교 산학협력단 GLYCATED FC VARIANTS WITH IMPROVED BINDING AFFINITY FOR FCγRIIIA US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes WO2023053282A1 (en) 2021-09-29 2023-04-06 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent for use in treatment of cancer KR20240099190A (en) 2021-09-30 2024-06-28 씨젠 인크. B7-H4 antibody drug conjugate for cancer treatment WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus KR20240082388A (en) 2021-10-08 2024-06-10 추가이 세이야쿠 가부시키가이샤 Method for preparing prefilled syringe formulations WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy EP4423126A1 (en) 2021-10-29 2024-09-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody TW202342095A (en) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 Composition for treatment and prevention of covid-19 CA3236417A1 (en) 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses JP2024544885A (en) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド Anti-interleukin-33 antibodies and uses thereof EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody CA3235206A1 (en) 2021-11-16 2023-05-25 Davide BASCO Novel molecules for therapy and diagnosis IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab MX2024006006A (en) 2021-11-17 2024-08-27 Disc Medicine Inc METHODS FOR TREATING ANEMIA FROM KIDNEY DISEASE. AU2022396102A1 (en) 2021-11-23 2024-07-11 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody US20250027067A1 (en) 2021-11-24 2025-01-23 Formycon Ag Improved ace2 fusion proteins WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins EP4445911A1 (en) 2021-12-06 2024-10-16 Beijing SoloBio Genetechnology Co., Ltd. Bispecific antibody that specifically binds to klebsiella pneumoniae o2 and o1 antigens, and composition AU2022414067A1 (en) 2021-12-15 2024-05-23 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof US20240425568A1 (en) 2021-12-17 2024-12-26 Viiv Healthcare Company Combination therapies for hiv infections and uses thereof EP4448579A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use JP2024547020A (en) 2021-12-17 2024-12-26 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド Anti-OX40 antibodies, multispecific antibodies and methods of use thereof CR20240246A (en) 2021-12-20 2024-07-19 Hoffmann La Roche AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM AU2023206045A1 (en) 2022-01-07 2024-08-22 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins. CA3236108A1 (en) 2022-01-18 2023-07-27 Paul Sebastian VAN DER WONING Galectin-10 antibodies TW202340251A (en) 2022-01-19 2023-10-16 美商建南德克公司 Anti-notch2 antibodies and conjugates and methods of use WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof JP2025503987A (en) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド Tumor-infiltrating lymphocytes engineered to express a payload WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof TW202342510A (en) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 Antibodies CN119421901A (en) 2022-03-03 2025-02-11 耶鲁大学 Humanized 3E10 antibodies, variants and antigen binding fragments thereof EP4490173A1 (en) 2022-03-07 2025-01-15 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses CN119173278A (en) 2022-03-10 2024-12-20 维硕公司 Antibody-conjugated drugs and uses thereof CN119173532A (en) 2022-03-11 2024-12-20 詹森药业有限公司 Multispecific antibodies and their uses AU2023232448A1 (en) 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof IL315541A (en) 2022-03-11 2024-11-01 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer AU2023236386A1 (en) 2022-03-18 2024-10-10 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof US20240103010A1 (en) 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use CN119095880A (en) 2022-03-28 2024-12-06 豪夫迈·罗氏有限公司 Interferon gamma variants and antigen-binding molecules comprising these variants IL316022A (en) 2022-03-30 2024-11-01 Janssen Biotech Inc A method for the treatment of mild to moderate psoriasis with a specific IL-23 antibody TW202405009A (en) 2022-03-30 2024-02-01 瑞士商諾華公司 Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof CN119487067A (en) 2022-04-01 2025-02-18 基因泰克公司 Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies AU2023250038A1 (en) 2022-04-08 2024-11-14 Ac Immune Sa Anti-tdp-43 binding molecules AU2023253705A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of therapeutic proteins and methods of use WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof AU2023262192A1 (en) 2022-04-29 2024-12-05 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same US12060426B2 (en) 2022-04-29 2024-08-13 23Andme, Inc. Anti-ULBP6 antibodies EP4519322A1 (en) 2022-05-03 2025-03-12 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof CN119487065A (en) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 Antibodies specifically recognizing GDF15 and uses thereof EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist EP4522640A1 (en) 2022-05-10 2025-03-19 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist AR129268A1 (en) 2022-05-11 2024-08-07 Hoffmann La Roche ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody WO2023232036A1 (en) 2022-05-31 2023-12-07 明济生物制药（北京）有限公司 Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof TW202421661A (en) 2022-06-10 2024-06-01 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 Igf1r antibodies AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use KR20250024831A (en) 2022-06-15 2025-02-19 바이오버라티브 유에스에이 인코포레이티드 Anti-complement C1s antibody formulation WO2023250507A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes TW202417042A (en) 2022-07-13 2024-05-01 美商建南德克公司 Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof CN119604530A (en) 2022-07-19 2025-03-11 基因泰克公司 Administration of Therapeutic Antibodies Using Anti-FCRH5/Anti-CD3 Bispecific Antibodies TW202417504A (en) 2022-07-22 2024-05-01 美商建南德克公司 Anti-steap1 antigen-binding molecules and uses thereof AR129991A1 (en) 2022-07-22 2024-10-23 Bristol Myers Squibb Co ANTIBODIES THAT BIND HUMAN PAD4 AND THEIR USES AR130041A1 (en) 2022-07-27 2024-10-30 Cephalon Llc ANTI-TL1A ANTIBODIES FORMULATIONS IL318428A (en) 2022-07-27 2025-03-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors CN119698274A (en) 2022-08-19 2025-03-25 亿一生物医药开发(上海)有限公司 Formulations comprising G-CSF and uses thereof AU2023329062A1 (en) 2022-08-25 2025-03-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and uses thereof WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies TW202417056A (en) 2022-08-29 2024-05-01 日商第一三共股份有限公司 Antibody-drug conjugate having fc mutations WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof AR130550A1 (en) 2022-09-21 2024-12-18 Sanofi Biotechnology HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USE WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl) WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein TW202421664A (en) 2022-10-07 2024-06-01 美商建南德克公司 Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies TW202432574A (en) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof TW202434286A (en) 2022-11-08 2024-09-01 美商建南德克公司 Compositions and methods of treating childhood onset idiopathic nephrotic syndrome WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules TW202435917A (en) 2022-11-17 2024-09-16 美商西雅圖遺傳學公司 Ceacam5 antibody-drug conjugates and methods of use thereof WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody TW202434306A (en) 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 Anti-cea antibody drug conjugates and methods of use EP4382120A1 (en) 2022-12-05 2024-06-12 Institut Regional du Cancer de Montpellier Anti-slc1a4 monoclonal antibodies and uses thereof EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates TW202430560A (en) 2023-01-06 2024-08-01 美商拉森醫療公司 Anti-il-18bp antibodies TW202434642A (en) 2023-01-06 2024-09-01 美商拉森醫療公司 ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE TW202432591A (en) 2023-01-06 2024-08-16 美商拉森醫療公司 Anti-il-18bp antibodies WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof TW202432607A (en) 2023-01-18 2024-08-16 美商建南德克公司 Multispecific antibodies and uses thereof WO2024153168A2 (en) 2023-01-19 2024-07-25 Beigene, Ltd. Anti-cmet antibodies and methods of use WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates TW202436339A (en) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 Use for treating cancer selected from non-small cell lung cancer or triple negative breast cancer WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab WO2024182714A1 (en) 2023-03-02 2024-09-06 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs TW202436343A (en) 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1 and cd16a antibodies and methods of use WO2024183637A1 (en) 2023-03-03 2024-09-12 Beigene Switzerland Gmbh Muc1 antibodies and methods of use WO2024183636A1 (en) 2023-03-03 2024-09-12 Beigene Switzerland Gmbh Cd16a antibodies and methods of use TW202436345A (en) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Anti-cd3 multispecific antibodies and methods of use WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use TW202436354A (en) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Anti-cldn6 antibodies and methods of use WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof TW202440636A (en) 2023-03-21 2024-10-16 美商傳記５５有限公司 Cd19/cd38 multispecific antibodies WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping WO2024200846A1 (en) 2023-03-30 2024-10-03 272BIO Limited Gnrh-binding polypeptides and uses thereof WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies US20240327522A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma WO2024263761A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Antibodies and uses thereof WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer WO2025003753A1 (en) 2023-06-26 2025-01-02 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer WO2025002410A1 (en) 2023-06-30 2025-01-02 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators WO2025021790A2 (en) 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof WO2025041077A1 (en) 2023-08-23 2025-02-27 Sanofi Ctla-4-based lysosomal degraders and uses thereof WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof